InMode Overview
InMode is a global provider of energy-based minimally invasive and noninvasive aesthetic solutions. The company has developed and commercialized products utilizing medically accepted radio-frequency (RF) energy technology, which can penetrate deep into the subdermal fat layer to allow adipose tissue remodeling. The company's technologies are used by physicians to remodel subdermal adipose, or fatty tissue, through a variety of procedures, including liposuction with simultaneous skin tightening, face and body contouring, and ablative skin rejuvenation treatments. InMode offers effective medical aesthetic solutions with BodyTite, Optimas, Votiva, Contoura, EmbraceRF, Evoke, Evolve, and Triton workstations.
Latest News
growth-negative
Estimating The Intrinsic Value Of InMode Ltd. (NASDAQ:INMD)
The article discusses the valuation of InMode Ltd. using the Discounted Cash Flow (DCF) model to estimate its intrinsic value. The analysis suggests that InModes current share price of $14.71 is close to its fair value estimate of $15.52. The analyst price target for InMode is $16.65, which is 7.3% higher than the estimated fair value. The DCF model used in the analysis considers two stages of growth: an initial period with a higher growth rate and a subsequent period with a stable growth rate. The article provides detailed projections of InModes future cash flows and their present value, indicating a conservative growth outlook.
growth-positive
InMode to Participate in Upcoming Investor Conferences
InMode Ltd., a global leader in innovative medical technologies, announced its participation in several investor conferences in November. The company, known for its advanced radiofrequency technology, will be represented by its Chief Financial Officer, Yair Malca, and Chief Executive Officer, Moshe Mizrahy, at events in Palm Beach Gardens, London, and New York. These conferences provide InMode with opportunities to engage with investors and showcase its comprehensive line of products used in various medical fields such as plastic surgery, gynecology, and dermatology. The participation in these events is indicative of InModes growth strategy and commitment to expanding its market presence.
growth-negative
Can InMode’s (INMD) Steady Guidance Reveal New Clues About Its Management Credibility?
InMode Ltd. has reaffirmed its revenue guidance for the third quarter and full year 2025, projecting revenues of US$92.5 million to US$93.0 million for Q3 and US$365 million to US$375 million for the year. This consistency in projections comes amid a backdrop of shifting market conditions and concerns over reduced consumer spending in the U.S., which remains a critical factor for the companys outlook. The upcoming third-quarter results, set to be released on November 5, 2025, are anticipated to provide further insights into demand trends for InModes minimally invasive aesthetic treatments. Despite the steady revenue guidance, the companys long-term forecasts indicate a slight decline in revenue and earnings by 2028, reflecting ongoing challenges in the market.
growth-positive
InMode to Report Third Quarter 2025 Financial Results and Hold Conference Call on November 5, Expects Q3 Revenue Between $92.5M-$93.0M, Reiterates FY 2025 Guidance Between $365M-$375M
InMode Ltd., a leading provider of innovative medical technologies, announced its preliminary financial results for the third quarter of 2025. The company expects revenue to be between $92.5 million and $93.0 million, with a non-GAAP gross margin ranging from 77% to 79%. The full-year revenue is projected to be between $365 million and $375 million, aligning with prior guidance. InMode will host a conference call on November 5, 2025, to discuss these results. The call will feature key executives, including CEO Moshe Mizrahy, CFO Yair Malca, and CTO Dr. Michael Kreindel. The event will be webcast live, with a replay available until November 19, 2025.
growth-positive
/PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its...
InMode Ltd., a leading provider of innovative medical technologies, announced its preliminary financial results for the third quarter of 2025. The company expects revenue to range between $92.5 million and $93.0 million, with a non-GAAP gross margin between 77% and 79%. The full-year revenue projection remains consistent with prior guidance, estimated between $365 million and $375 million. InMode will host a conference call on November 5, 2025, to discuss these results. The company specializes in developing and marketing devices using novel radio frequency technology for various medical fields, including plastic surgery and dermatology. The announcement is seen as growth-positive, reflecting stable financial performance.
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $70M |
| Last funding | $70M |
| Stage | Public |
| Rounds | 1 |
| Investors | 0 |
Team Members
4
Employees: 500+
Web & Social Links
| Website | inmodemd.com/ |
| Careers | Careers page |
Locations
Ha-Carmel Street 1, Yokne'am Illit, Israel
100 Leek Crescent #15 Richmond Hill, ON
Bakewell, Derbyshire, UK
20996 Bake Parkway, Lake Forest, CA, USA
Photos & Videos
5 item(s)
InMode Business
Business models
B2B
Product stage
Released
Employees
500+
Sector
Health Tech & Life SciencesMedical DevicesAesthetic DevicesTarget Customer
Healthcare & Life SciencesHealthcareProvidersMedical Devices IndustryMedical EquipmentCore Technology
CommunicationsRadio FrequencySensingLaserSemiconductors & ElectronicsTags (13)
rf-technologyclinicsnon-surgicalnon-invasiveskin-caremedical-devicespain-freedermatologyminimally-invasivedoctorsmedical-technologieslaserswellnessGeographic Markets
United StatesUnited KingdomJapanGermanyHong KongCanadaInMode Financials
$70M
Total funding
—
Capital raised
$70M
Last funding
Public
Funding stage
1
Total rounds
0
Investors
Public Offering / Exit
POEvent
Aug 2019
Undisclosed
Mergers & Acquisitions
MNAEvent
Jul 2023
Undisclosed
InMode Lifecycle
All Events
POEvent
Aug 2019
Undisclosed
MNAEvent
Jul 2023
Undisclosed
InMode News
280 articles
growth-negative
Estimating The Intrinsic Value Of InMode Ltd. (NASDAQ:INMD)
The article discusses the valuation of InMode Ltd. using the Discounted Cash Flow (DCF) model to estimate its intrinsic value. The analysis suggests that InModes current share price of $14.71 is close to its fair value estimate of $15.52. The analyst price target for InMode is $16.65, which is 7.3% higher than the estimated fair value. The DCF model used in the analysis considers two stages of growth: an initial period with a higher growth rate and a subsequent period with a stable growth rate. The article provides detailed projections of InModes future cash flows and their present value, indicating a conservative growth outlook.
growth-positive
InMode to Participate in Upcoming Investor Conferences
InMode Ltd., a global leader in innovative medical technologies, announced its participation in several investor conferences in November. The company, known for its advanced radiofrequency technology, will be represented by its Chief Financial Officer, Yair Malca, and Chief Executive Officer, Moshe Mizrahy, at events in Palm Beach Gardens, London, and New York. These conferences provide InMode with opportunities to engage with investors and showcase its comprehensive line of products used in various medical fields such as plastic surgery, gynecology, and dermatology. The participation in these events is indicative of InModes growth strategy and commitment to expanding its market presence.
growth-negative
Can InMode’s (INMD) Steady Guidance Reveal New Clues About Its Management Credibility?
InMode Ltd. has reaffirmed its revenue guidance for the third quarter and full year 2025, projecting revenues of US$92.5 million to US$93.0 million for Q3 and US$365 million to US$375 million for the year. This consistency in projections comes amid a backdrop of shifting market conditions and concerns over reduced consumer spending in the U.S., which remains a critical factor for the companys outlook. The upcoming third-quarter results, set to be released on November 5, 2025, are anticipated to provide further insights into demand trends for InModes minimally invasive aesthetic treatments. Despite the steady revenue guidance, the companys long-term forecasts indicate a slight decline in revenue and earnings by 2028, reflecting ongoing challenges in the market.
growth-positive
InMode to Report Third Quarter 2025 Financial Results and Hold Conference Call on November 5, Expects Q3 Revenue Between $92.5M-$93.0M, Reiterates FY 2025 Guidance Between $365M-$375M
InMode Ltd., a leading provider of innovative medical technologies, announced its preliminary financial results for the third quarter of 2025. The company expects revenue to be between $92.5 million and $93.0 million, with a non-GAAP gross margin ranging from 77% to 79%. The full-year revenue is projected to be between $365 million and $375 million, aligning with prior guidance. InMode will host a conference call on November 5, 2025, to discuss these results. The call will feature key executives, including CEO Moshe Mizrahy, CFO Yair Malca, and CTO Dr. Michael Kreindel. The event will be webcast live, with a replay available until November 19, 2025.
growth-positive
/PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its...
InMode Ltd., a leading provider of innovative medical technologies, announced its preliminary financial results for the third quarter of 2025. The company expects revenue to range between $92.5 million and $93.0 million, with a non-GAAP gross margin between 77% and 79%. The full-year revenue projection remains consistent with prior guidance, estimated between $365 million and $375 million. InMode will host a conference call on November 5, 2025, to discuss these results. The company specializes in developing and marketing devices using novel radio frequency technology for various medical fields, including plastic surgery and dermatology. The announcement is seen as growth-positive, reflecting stable financial performance.
growth-positive
Sanuwave Health (SNWV) Surges 9.1%: Is This an Indication of Further Gains?
Sanuwave Health Inc. experienced a significant 9.1% increase in its stock price, closing at $40.82, driven by record preliminary Q3 2025 revenues of $11.4–$11.6 million. This marks a 22–24% year-over-year and 12–14% sequential increase, despite being below prior guidance. September was the highest revenue month on record, indicating strong demand and positive investor sentiment. The company is expected to report quarterly earnings of $0.37 per share, a 105.7% year-over-year increase, with revenues projected at $12.37 million, up 32.2% from the previous year. The positive trend in earnings estimate revisions suggests potential for further stock price appreciation. Sanuwave Health is part of the Zacks Medical - Products industry and currently holds a Zacks Rank #2 (Buy).
growth-negative
Did DOMA Perpetual’s Push for Major Buybacks Just Shift InMode’s (INMD) Investment Narrative?
On September 9, 2025, DOMA Perpetual Capital Management LLC urged InMode Ltd.s Board to approve a 10% share buyback in Q4 2025 and another 10% in Q1 2026, highlighting concerns about management and capital allocation. This activist intervention emphasizes InModes substantial cash reserves and pressures the Board to prioritize shareholder interests. While the push for share buybacks draws attention to InModes strong balance sheet, it does not directly impact the companys short-term catalyst of international sales expansion or address the risk of sluggish demand for capital equipment. The article also discusses InModes financial forecasts and varying community fair value estimates.
PIPE/POManagement Changes
growth-negative
Assessing InMode (INMD) Valuation as Shareholder Activism Escalates Over Buyback Push
InMode is currently facing pressure from DOMA Perpetual Capital Management, a significant shareholder, to initiate two substantial share buybacks. DOMA argues that InModes cash reserves and current valuation make buybacks prudent. Despite a modest rebound in share price recently, InModes performance has been lackluster, with a 12% decline since January. The company is seen as undervalued by nearly 9% compared to its estimated fair value, with potential growth driven by international expansion in markets like Thailand and Argentina. However, regulatory challenges and shifts towards lower-margin treatments could threaten this outlook.
growth-negative
DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Return Capital to the Shareholders
DOMA Perpetual Capital Management LLC, a significant shareholder of InMode Ltd., has urged the companys board to execute a 10% stock buyback in Q4 2025 and another in Q1 2026. The letter criticizes InModes management for poor leadership decisions, including the firing of the US head of sales and negative public comments on capital allocation. These actions have reportedly led to a decline in the companys valuation. Despite holding significant cash reserves and no debt, InModes management has been accused of not acting in the best interests of shareholders. DOMA emphasizes the need for the board to fulfill its fiduciary duties.
Management Changes
growth-negative
Do Options Traders Know Something About InMode Stock We Don't?
The article discusses the recent activity in the options market concerning InMode Ltd., highlighting the high implied volatility of the Jan 16, 2025 $03.00 Put option. This suggests that investors expect significant stock movement, potentially due to an upcoming event. InMode is currently rated as a Zacks Rank #5 (Strong Sell) in the Medical-Products industry, with a downward revision in earnings estimates for the current quarter. The high implied volatility could indicate a trading opportunity, as options traders might sell premium to capture decay, hoping the stock does not move as much as expected.
growth-positive
/PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial...
InMode Ltd., a global provider of innovative medical technologies, announced that its Chief Financial Officer, Yair Malca, will present at the Baird 2025 Global Healthcare Conference in New York on September 10, 2025. The presentation will be part of a fireside chat moderated by Jeff Johnson, a Senior Research Analyst. InMode will also conduct one-on-one investor meetings during the event. The company specializes in developing and marketing devices using novel radio frequency technology for various medical fields. The announcement includes forward-looking statements about InModes future financial performance and strategic plans.
growth-positive
InMode to Present at Baird 2025 Global Healthcare Conference
InMode Ltd., a leading provider of innovative medical technologies, announced that its CFO, Yair Malca, will present at the Baird 2025 Global Healthcare Conference in New York on September 10, 2025. The presentation will include a fireside chat moderated by Jeff Johnson, Senior Research Analyst, and will be available via live webcast. InMode will also conduct one-on-one investor meetings during the event. The company specializes in developing and marketing devices using novel radio frequency technology for various medical fields. The press release includes forward-looking statements about InModes future financial and operational performance.
growth-positive
InMode Ltd.'s (NASDAQ:INMD) Stock Been Rising: Are Strong Financials Guiding The Market?
The article discusses InModes recent stock performance, highlighting a 3.3% increase over the past month. It focuses on the companys return on equity (ROE) as a measure of profitability, noting that InModes ROE of 28% is significantly higher than the industry average of 11%. This high ROE has contributed to a net income growth of 14% over the last five years, aligning with the industry average growth rate of 13%. The article suggests that InModes strong financial fundamentals and profitability could be influencing its market performance positively.
growth-positive
InMode to Participate in Upcoming Investor Conferences
InMode Ltd., a leading global provider of innovative medical technologies, announced its participation in two investor conferences in August. The company will be represented by its CEO, Moshe Mizrahy, at the 10th Annual Needham Virtual MedTech & Diagnostics Conference, and by its CFO, Yair Malca, at the Canaccord 45th Annual Global Growth Conference. InMode specializes in developing, manufacturing, and marketing devices using novel radio frequency technology for various medical fields, including plastic surgery and dermatology. The company aims to enable new surgical procedures and improve existing treatments. The press release also includes forward-looking statements about InModes future financial performance, cautioning readers about potential risks and uncertainties.
growth-positive
/PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation in the following...
InMode Ltd., a leading provider of innovative medical technologies, announced its participation in two major investor conferences in August. The company will be represented by its CEO, Moshe Mizrahy, and CFO, Yair Malca, at the 10th Annual Needham Virtual MedTech & Diagnostics Conference and the Canaccord 45th Annual Global Growth Conference. InMode specializes in developing, manufacturing, and marketing devices using novel radio frequency technology, offering products across various medical fields. The announcement includes forward-looking statements about future financial performance, with a cautionary note on the inherent risks and uncertainties. The company emphasizes its commitment to advancing surgical procedures and improving existing treatments.
growth-positive
InMode Reports Second Quarter 2025 Financial Results: Quarterly Revenue of $95.6 Million, 80% Gross Margins
InMode Ltd., a leading provider of medical technologies, announced its financial results for Q2 2025, reporting a revenue increase to $95.6 million from $86.4 million in Q2 2024. Despite a 6% decrease in revenues from consumables and services, the company achieved a GAAP operating income of $22.9 million and a non-GAAP operating income of $26.3 million. InModes international sales, particularly in Europe, reached record highs, offsetting some challenges in the U.S. market due to macroeconomic uncertainties. The company maintains a strong cash position of $510.7 million, allowing it to retain talent and expand globally. Management remains focused on mitigating the impact of U.S. tariffs on gross margins.
growth-positive
InMode: Q2 Earnings Snapshot
InMode Ltd., based in Yokneam, Israel, reported a net income of $26.7 million for its second quarter, translating to 42 cents per share, or 47 cents when adjusted for stock option expenses. The company, known for its cosmetic surgery devices, generated $95.6 million in revenue during this period. Looking ahead, InMode anticipates full-year earnings to be between $1.55 and $1.59 per share, with projected revenue ranging from $365 million to $375 million. This positive financial performance suggests a growth-positive outlook for the company.
growth-negative
Are Options Traders Betting on a Big Move in InMode Stock?
The article discusses the high implied volatility in the options market for InMode Ltd., indicating that investors expect significant stock movement. InMode is currently rated as a Strong Sell by Zacks, with its industry ranking in the bottom 29%. Analysts have revised their earnings estimates downwards, suggesting a negative outlook. The high implied volatility presents a potential trading opportunity for options traders looking to sell premium. The article also mentions Zacks Investment Researchs strategies for trading and offers a free stock analysis report for InMode Ltd.
growth-positive
InMode (INMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
InMode is anticipated to report a year-over-year increase in earnings and revenues for the quarter ending June 2025. The earnings report, expected on July 30, could positively impact the stock price if results exceed expectations. The company is projected to post quarterly earnings of $0.43 per share, a 26.5% increase from the previous year, with revenues expected to rise by 10.5% to $95.5 million. The consensus EPS estimate has been revised downward by 9.76% over the past 30 days. The Zacks Earnings ESP model suggests a positive earnings surprise is likely, especially if combined with a strong Zacks Rank.
growth-negative
Canaccord Genuity Maintains a Hold Rating on InMode Ltd. (INMD)
InMode Ltd., a medical device company specializing in minimally invasive aesthetic products, has revised its full-year guidance for 2025 due to ongoing economic uncertainty and market weakness in the US. The company now expects its full-year revenue to be between $365 million and $375 million, down from the previous guidance of $395 million to $405 million. Despite the companys potential, the article suggests that AI stocks may offer better investment opportunities. The report by Canaccord Genuity maintains a Hold rating on InMode with a price target of $15.00. The article highlights the companys released products and the challenges it faces in the current economic climate.
Product StagePublic Trading
growth-negative
InMode to Report Second Quarter 2025 Financial Results and Hold Conference Call on July 30, Expects Q2 Revenue Between $95.4M-$95.5M, Decreases Full Year 2025 Revenue Guidance to be Between $365M-$375M
InMode Ltd., a global provider of medical technologies, announced its preliminary financial results for the second quarter of 2025. Due to ongoing market weakness and uncertainty in the U.S. economic outlook, the company has revised its full-year revenue guidance downward to a range of $365 million to $375 million, from the previous $395 million to $405 million. The expected revenue for Q2 2025 is between $95.4 million and $95.5 million, with a non-GAAP gross margin of 79% to 80%. A conference call to discuss these results is scheduled for July 30, 2025.
growth-negative
Positive earnings growth hasn't been enough to get InMode (NASDAQ:INMD) shareholders a favorable return over the last three years
InMode Ltd. (NASDAQ:INMD) has experienced a 38% decline in share price over the past three years, underperforming the markets 65% return. Despite a recent 6.8% bounce in the past week, long-term shareholders remain in the red. Interestingly, the company managed to grow its earnings per share (EPS) by 11% annually during this period, suggesting a disconnect between EPS growth and share price performance. The companys revenue has remained healthy, indicating that the share price drop might be due to changing investor sentiment rather than fundamental business issues. Over the last year, InMode shareholders lost 13%, while the broader market gained 15%. Long-term shareholders have seen a modest 3% annual gain over five years.
growth-positive
InMode Ltd. (NASDAQ:INMD) is largely controlled by institutional shareholders who own 72% of the company
The article discusses the ownership structure of InMode Ltd., highlighting that institutional investors hold a significant portion of the companys shares, with 72% ownership. This level of institutional investment is generally seen as a positive indicator for the company, as it suggests credibility among professional investors. The largest shareholder is BlackRock, Inc., with 8.9% of shares, followed by insiders Moshe Mizrahy and Michael Kreindel, who hold 5.5% and 4.9% respectively. The article also touches on the potential impact of AI on healthcare, noting that InMode is among the companies working in this space.
growth-negative
InMode Response Letter to DOMA by Moshe Mizrahy, CEO, Dated May 28, 2025
InMode Ltd., a leading provider of medical technologies, addressed concerns raised by DOMA Perpetual Capital Management LLC in a public letter. InModes CEO responded to DOMAs CEO, Pedro Escudero, emphasizing the companys commitment to returning capital to shareholders through a $508 million share buyback over the past 2.5 years. The letter also addressed concerns about moving production capacity out of Israel, highlighting the importance of proximity to engineering and R&D teams. Additionally, the CEO explained the slowdown in North American sales, attributing it to macroeconomic factors and financing difficulties rather than management issues. Despite challenges, InMode continues to supply its products globally without compromising quality.
growth-negative
/PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today sent a letter to DOMA Perpetual...
InMode Ltd., a global provider of innovative medical technologies, responded to a public letter from DOMA Perpetual Capital Management LLCs CEO, Pedro Escudero. The letter addressed several issues, including InModes share buyback program, production capacity, sales organization in North America, and the CEOs management style. InModes CEO, Moshe Mizrahy, defended the companys strategies and his leadership, emphasizing the companys commitment to quality and timely delivery despite challenges. The letter also highlighted macroeconomic factors affecting North American sales. InModes forward-looking statements caution about potential risks and uncertainties in future financial performance.
growth-positive
Is There An Opportunity With InMode Ltd.'s (NASDAQ:INMD) 35% Undervaluation?
The article discusses the valuation of InMode Ltd. (NASDAQ:INMD) using the Discounted Cash Flow (DCF) model. The analysis estimates the companys fair value at US$21.85 per share, suggesting that the current share price of US$14.23 is undervalued by approximately 35%. The analyst price target of US$17.25 is also noted to be 21% less than the estimated fair value. The DCF model used is a 2-stage growth model, accounting for different growth rates in the initial and stable stages. The article provides projected cash flows for the next ten years, with a present value of US$651 million. This analysis indicates a positive growth outlook for InMode.
growth-negative
Do Options Traders Know Something About InMode Stock We Don't?
The article discusses the recent high implied volatility in the options market for InMode Ltd. (INMD), indicating that investors expect significant stock movement. Despite being ranked as a Strong Sell by Zacks in the Medical - Products industry, one analyst has increased their earnings estimate for the current quarter. This suggests potential trading opportunities for options traders, who may sell premium to capture decay if the stock does not move as expected. The article highlights the potential for profit and risk reduction through strategic options trading.
growth-positive
InMode Announces Health Canada Certification of the IgniteRF Platform with the New QuantumRF Technology
InMode Ltd., a leading provider of medical technologies, has received Health Canada certification for its IgniteRF platform. This platform offers a suite of minimally invasive radiofrequency solutions for face and body treatments. IgniteRF includes nine proprietary technologies, such as QuantumRF, Morpheus8 Burst, and BodyTite Turbo, designed to deliver natural-looking results with minimal downtime. The certification allows InMode to expand its presence in Canada, providing advanced technologies to physicians seeking effective, minimally invasive procedures. The companys CEO, Moshe Mizrahy, highlighted the expansion as a step towards offering exceptional results to more doctors and patients globally.
Product Stage
growth-positive
/PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, is pleased to announce Health Canada certification of...
InMode Ltd., a global leader in innovative medical technologies, has announced the Health Canada certification of its IgniteRF platform. This advanced platform offers minimally invasive radiofrequency solutions for face and body treatments. IgniteRF includes nine proprietary technologies, such as QuantumRF, Morpheus8 Burst, and BodyTite Turbo, designed to provide natural-looking results with minimal downtime. The certification allows InMode to expand its global presence and offer its cutting-edge technologies to more physicians in Canada. The companys CEO, Moshe Mizrahy, emphasized the importance of this expansion in delivering exceptional results to patients seeking youthful appearances.
Product Stage
growth-negative
DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Resume Share Repurchase Program
DOMA Perpetual Capital Management LLC, a significant stockholder of InMode Ltd., has urged the companys Board of Directors to resume and accelerate stock buybacks and to replace the current CEO, Moshe Mizrahy. DOMA has expressed concerns over the companys capital allocation strategy and the CEOs public statements, which they believe have negatively impacted InModes stock price and financial performance. The letter highlights the need for the Board to act in the best interest of shareholders by addressing the CEOs management style and financial decisions, which are seen as detrimental to the companys long-term value.
Management Changes
growth-positive
InMode to Present at Upcoming Investor Conferences and Events
InMode Ltd., a leading global provider of innovative medical technologies, announced its participation in several upcoming investor conferences. The company will engage in virtual and in-person presentations, including a fireside chat at BNPs 3rd Annual Aesthetics Day and an in-person investor bus tour at InModes North American headquarters. InMode specializes in developing, manufacturing, and marketing devices that utilize novel radiofrequency technology to enhance surgical procedures and treatments across various medical fields. These events aim to strengthen investor relations and showcase InModes comprehensive line of products. The company is not currently seeking investment or undergoing any structural changes.
growth-negative
We Think That There Are More Issues For InMode (NASDAQ:INMD) Than Just Sluggish Earnings
The article discusses the recent earnings report of InMode Ltd., highlighting investor disappointment due to soft profit numbers. The analysis points to a high accrual ratio of 0.71, indicating weaker free cash flow compared to reported profits, which is a negative indicator for future earnings. InModes free cash flow was US$122 million, falling short of its US$175.8 million profit. Additionally, the company benefited from a one-off tax benefit of US$36 million, which may not recur, potentially overstating the companys sustainable earnings. These factors contribute to a growth-negative outlook for InMode.
growth-positive
InMode Granted Injunction Against Counterfeit Sales of Morpheus8 Radio Frequency Microneedling Devices and Needle Cartridges
InMode Ltd., a leading provider of medical technologies, secured a legal victory as the US District Court for the Central District of California granted a default judgment against DHGate sellers for selling counterfeit goods. The court awarded InMode a permanent injunction and damages, protecting its trademark rights and ensuring consumer safety. The injunction freezes the assets and halts the listings of the counterfeit sellers. InModes CEO, Moshe Mizrahy, emphasized the companys commitment to combating fraudulent practices and protecting consumers. InMode has also established a Verified Provider Program for its Morpheus8 device, ensuring patients receive care from authorized providers using genuine technology.
growth-negative
InMode Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
InMode Ltd. recently released its quarterly earnings report, which led to a negative market reaction, with shares dropping by 7.7%. The companys revenues were in line with forecasts at $78 million, but earnings per share were 18% below expectations. Analysts have revised their earnings models, predicting a 43% drop in EPS to $1.48 by 2025, compared to previous forecasts of $1.74. The average price target for InModes stock fell by 19% to $17.25. Revenue is expected to decline by 2.3% annually until 2025, contrasting with the historical growth rate of 17% over the past five years. This performance is notably worse than the industry average, which is expected to grow by 8% annually.
growth-negative
InMode Ltd (INMD) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic ...
InMode Ltd reported a 3% decrease in revenue for Q1 2025 compared to the previous year, with international sales accounting for 49% of total sales. Despite the decline, the company maintained a strong balance sheet with $512.9 million in cash and cash equivalents. The company plans to expand its product portfolio by unveiling a new platform for the wellness market. InMode avoided layoffs despite economic challenges and completed its fifth share purchase program, returning over $412 million to shareholders. The US market faced significant headwinds, with revenue share dropping to 50%. The company anticipates a reduction in operating margins due to continued pressure in the US market and international revenue growth.
Product StageCustomersExpand
growth-negative
InMode First Quarter 2025 Earnings: EPS Misses Expectations
InMode reported a decline in revenue and net income for the first quarter of 2025 compared to the same period in 2024. Revenue decreased by 3.0% to $77.9 million, while net income fell by 23% to $18.2 million. The profit margin also decreased from 30% to 23%, primarily due to higher expenses. Earnings per share (EPS) missed analyst estimates by 18%, coming in at $0.27. Despite these declines, revenue is forecasted to grow at an average of 3.5% annually over the next three years, although this is below the 8.0% growth forecast for the US Medical Equipment industry. The companys shares have dropped by 3.6% over the past week.
growth-negative
InMode Reports First Quarter 2025 Financial Results; Quarterly Revenue of $77.9 Million Represents 3% Year-Over-Year Decrease
InMode Ltd., a leading provider of medical technologies, reported its financial results for Q1 2025, showing a decrease in quarterly revenues to $77.9 million from $80.3 million in Q1 2024. The company completed a share repurchase program, returning $127 million to shareholders. Despite a challenging macroeconomic environment and weakened consumer demand, InMode achieved record international performance, particularly in Europe. The company remains focused on innovation and operational excellence, highlighted by the recent launch of its OptimasMAX and Ignite platforms. However, the overall financial performance was negatively impacted by external factors.
growth-negative
InMode (INMD) Lags Q1 Earnings Estimates
InMode reported quarterly earnings of $0.31 per share, missing the Zacks Consensus Estimate of $0.33 per share, marking an earnings surprise of -6.06%. This is a decline from $0.45 per share a year ago. The companys revenue for the quarter was $77.87 million, slightly surpassing the consensus estimate but lower than the $80.28 million from the previous year. Despite outperforming the market since the beginning of the year, InModes stock is expected to underperform in the near future due to an unfavorable trend in earnings estimate revisions, resulting in a Zacks Rank #4 (Sell).
growth-positive
InMode: Q1 Earnings Snapshot
InMode Ltd., a company based in Yokneam, Israel, reported earnings of $18.2 million for its first quarter, translating to a profit of 26 cents per share. Adjusted earnings, accounting for stock option expenses, were 31 cents per share. The company, which specializes in cosmetic surgery devices, generated $77.9 million in revenue during this period. InMode projects its full-year earnings to be between $1.64 and $1.68 per share. This report was generated using data from Zacks Investment Research.
growth-negative
/PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial...
InMode Ltd., a global provider of medical technologies, reported its financial results for Q1 2025, showing a decline in revenue to $77.9 million from $80.3 million in Q1 2024. The company completed a share repurchase program, buying back 6.95 million shares for $127 million. Despite a challenging macroeconomic environment and weakened consumer demand, InMode remains focused on innovation and operational excellence. The company launched new platforms, OptimasMAX and Ignite, to reinforce its commitment to aesthetics technology. InModes international performance was strong, particularly in Europe, while the U.S. market faced headwinds. The company maintains a robust cash position of $512.9 million and plans to continue disciplined capital allocation.
growth-negative
Earnings Preview: Envista (NVST) Q1 Earnings Expected to Decline
Envista is expected to report a year-over-year decline in earnings and revenues for the quarter ending March 2025. The anticipated earnings per share (EPS) is $0.21, reflecting a 19.2% decrease, while revenues are projected to be $609.03 million, down 2.3% from the previous year. The consensus EPS estimate has been revised downwards by 2.44% over the last 30 days. The Zacks Earnings ESP model suggests that a positive Earnings ESP reading could indicate an earnings beat, especially when combined with a strong Zacks Rank. The earnings report, expected on May 1, 2025, could influence the stock price depending on whether the actual results meet or exceed expectations.
growth-negative
Earnings Preview: InMode (INMD) Q1 Earnings Expected to Decline
InMode (INMD) is expected to report a year-over-year decline in earnings and lower revenues for the quarter ending March 2025. The anticipated earnings per share (EPS) is $0.33, a decrease of 26.7% from the previous year, with revenues projected at $77.4 million, down 3.6%. The consensus EPS estimate has been revised 2.27% higher in the last 30 days. The upcoming earnings report, expected on April 28, could influence the stock price depending on whether the actual results meet or exceed these estimates. The Zacks Earnings ESP model suggests that a positive Earnings ESP reading could indicate an earnings beat, especially when combined with a strong Zacks Rank.
growth-positive
InMode to Report First Quarter 2025 Financial Results and Hold Conference Call on April 28, 2025, Expects Q1 Revenue Between $77.2M-$77.5M, Reiterates FY 2025 Revenue Guidance Between $395M-$405M
InMode Ltd., a leading provider of innovative medical technologies, announced its preliminary financial results for the first quarter of 2025. The company expects revenue to range between $77.2 million and $77.5 million, with a non-GAAP gross margin of 78% to 79%. For the full year 2025, revenue is projected to be between $395 million and $405 million. InMode will host a conference call on April 28, 2025, to discuss these results, featuring presentations from key management figures. The company is finalizing its financial data, and the results are subject to adjustments before the official release.
growth-positive
/PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its...
InMode Ltd., a leading provider of innovative medical technologies, announced its preliminary financial results for the first quarter of 2025. The company expects revenue to be between $77.2 million and $77.5 million, with a non-GAAP gross margin of 78% to 79%. For the full year 2025, revenue is projected to range from $395 million to $405 million. InMode will host a conference call on April 28, 2025, to discuss these results. The company specializes in developing and marketing devices using novel radio frequency technology for various medical fields. The announcement is seen as growth-positive, reflecting strong financial performance and future revenue expectations.
growth-positive
InMode (INMD) Soars 6.8%: Is Further Upside Left in the Stock?
InModes shares rose by 6.8% to $15.46 in the last trading session, driven by a relief rally in global markets following a 90-day pause on U.S. tariff hikes. Despite a 23% loss over the past four weeks, the companys stock saw a significant volume of trades. InMode, a cosmetic surgery device maker, is expected to report quarterly earnings of $0.45 per share, unchanged from the previous year, with revenues projected to increase by 14.5% to $91.9 million. The stock holds a Zacks Rank #3 (Hold), indicating potential for future growth if earnings estimates improve.
growth-negative
Why InMode Ltd. (NASDAQ:INMD) Could Be Worth Watching
The article discusses the current valuation and stock price movement of InMode Ltd. (NASDAQ: INMD), highlighting its recent fluctuations on the NASDAQGS. Despite being undervalued with an intrinsic value of $22.00 compared to its current trading price of $16.30, the company faces a negative profit growth outlook of -9.7% over the next few years. This presents a higher risk for investors, although the undervaluation may offer a buying opportunity. The article suggests that potential investors should consider the risks associated with negative growth prospects, while current shareholders should evaluate their portfolio exposure to INMD.
growth-positive
HCI Group and Boise Cascade have been highlighted as Zacks Bull and Bear of the Day
The article discusses HCI Group, highlighting its strong performance in the insurance sector, particularly in property and casualty insurance. HCI Group is recognized as a top-performing stock, benefitting from the momentum in insurance stocks and making a series of 52-week highs. The company operates through its subsidiaries, offering residential insurance products and reinsurance programs. It also has a significant presence in real estate, owning and operating various properties. The article emphasizes the importance of investing in stocks within leading industry groups, noting that HCI Groups industry ranks in the top 18% of Zacks Ranked Industries, suggesting continued outperformance in the market.
growth-positive
3 Undervalued MedTech Stocks to Buy for 2025 Gains Amid S&P 500 Rally
The U.S. stock market experienced a significant rebound, with major indices like the Dow Jones, S&P 500, and Nasdaq Composite showing substantial gains. This rally was fueled by investor optimism regarding potentially less severe tariffs from President Trump, easing fears of a global trade war. The MedTech sector, which has lagged behind the broader market, stands to benefit from this rally, with companies like Phibro Animal Health, Fresenius Medical Care, and InMode poised for growth. The MedTech industry is undergoing a transformation driven by innovation, evolving regulations, and consumer-driven healthcare. Advances in CRISPR, next-generation sequencing, and AI-driven medical devices are expected to drive growth. Despite challenges in 2024, undervalued MedTech stocks could rebound strongly in 2025.
growth-positive
InMode to Present at the 24th Annual Needham Virtual Healthcare Conference
InMode Ltd., a leading global provider of innovative medical technologies, announced that its CEO, Moshe Mizrahy, and CFO, Yair Malca, will present at the 24th Annual Needham Virtual Healthcare Conference on April 8, 2025. The presentation will be a fireside chat moderated by Michael Matson, Senior Equity Analyst, and will be available via live webcast. InMode will also conduct one-on-one investor meetings on the same day. The company is known for developing, manufacturing, and marketing devices using novel radio frequency technology to enhance surgical procedures and treatments across various medical fields.
growth-positive
Is InMode (INMD) Stock Undervalued Right Now?
The article discusses InMode (INMD), highlighting its current status as a strong value stock according to Zacks Investment Research. InMode holds a Zacks Rank of #2 (Buy) and a Value grade of A, indicating it is undervalued compared to its industry peers. The companys P/E ratio is 9.48, significantly lower than the industry average of 21.60, and its P/B ratio is 1.84, compared to the industry average of 5.22. These metrics suggest that InMode is currently undervalued, making it an attractive option for value investors. The article emphasizes the importance of value investing and the potential of InMode as a strong market performer.
growth-positive
Is InMode Ltd.'s (NASDAQ:INMD) Recent Stock Performance Tethered To Its Strong Fundamentals?
InModes stock has risen by 5.4% over the past month, reflecting its strong financial performance. The article focuses on InModes Return on Equity (ROE), which stands at 26%, significantly higher than the industry average of 13%. This high ROE indicates effective reinvestment of shareholder capital and suggests a strong profitability ratio. Over the past five years, InMode has experienced a 19% net income growth, surpassing the industry average growth of 13%. The article suggests that InModes financial health and high ROE contribute to its positive stock performance and potential for future growth.
growth-positive
InMode Responds to Doma Perpetual's Letters
InMode Ltd., a leading provider of medical technologies, addressed concerns raised by DOMA Perpetual Capital Management LLC regarding its capital allocation strategy and shareholder returns. InMode clarified its commitment to returning capital efficiently, highlighting its ongoing buy-back program, which has returned approximately $500 million to shareholders since 2022. The company plans to continue this strategy through 2025, exploring additional capital returns to enhance shareholder value. InMode refuted the suggestion of a 30% tender offer due to tax inefficiencies and emphasized its focus on delivering value to shareholders while maintaining open communication with them.
growth-positive
/PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today sent a letter to DOMA Perpetual...
InMode Ltd., a global provider of medical technologies, addressed concerns raised by DOMA Perpetual Capital Management regarding its capital allocation and shareholder returns. InMode has been conducting share buy-backs and plans to return additional capital by the end of 2025. The company refuted claims about inefficiencies in capital return and staffing issues, emphasizing its strategic management changes and ongoing R&D investments. InMode is exploring M&A opportunities, having made offers to acquire companies in the injectable sector, although these were not accepted. The company remains committed to enhancing shareholder value through strategic capital allocation and potential acquisitions.
Management ChangesAcquisitionProduct Stage
growth-positive
InMode to Present at Upcoming Investor Conferences
InMode Ltd., a leading global provider of innovative medical technologies, announced its participation in two major investor conferences in March. The company will be represented by its Chief Financial Officer, Yair Malca, and Chief Executive Officer, Moshe Mizrahy. They will participate in the Barclays 27th Annual Global Healthcare Conference in Miami and the Oppenheimer 34th Annual Healthcare MedTech & Services Conference virtually. InMode specializes in developing, manufacturing, and marketing devices that utilize novel radiofrequency technology to enhance surgical procedures and treatments across various medical fields. The companys participation in these conferences is expected to positively impact its growth by engaging with investors and showcasing its advanced medical technologies.
growth-negative
InMode (INMD) Q4 2024 Earnings Call Transcript
InModes Q4 2024 earnings call highlighted a challenging year with a 20% decrease in revenue compared to 2023, attributed to macroeconomic factors and decreased demand for minimally invasive procedures. Despite these challenges, InMode focused on innovation, launching two new platforms, IgniteRF and OptimasMAX, which are expected to gain traction. The company returned $285 million to shareholders through share repurchases and announced a new repurchase program. Management changes were implemented in various regions to enhance sales and operations. InMode remains optimistic about future growth, supported by its strong balance sheet and innovative product portfolio.
Product StageInvestmentManagement Changes
growth-negative
InMode Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
InMode reported a revenue of US$394.8 million, down 20% from FY 2023, and a net income of US$181.3 million, down 8.4% from FY 2023. Despite the decline in revenue and net income, the profit margin increased to 46% from 40% due to lower expenses. Earnings per share (EPS) were US$2.29, slightly down from US$2.37 in FY 2023, but exceeded analyst estimates by 34%. Revenue missed analyst estimates by 1.8%. Looking forward, revenue is expected to grow at an average of 4.7% per annum over the next three years, which is below the 7.9% growth forecast for the US Medical Equipment industry. The companys shares have increased by 1.6% from a week ago.
growth-negative
InMode Ltd (INMD) Q4 2024 Earnings Call Highlights: Navigating Revenue Decline with Strategic ...
InMode Ltd reported a 20% decrease in total revenue for 2024 compared to 2023, largely due to decreased demand and high interest rates. International sales also saw a decline of 19% year-over-year. Despite these challenges, the company maintained a strong emphasis on R&D and launched two new platforms, IgniteRF and OptimasMax, with plans to introduce a fractional laser CO2 platform in 2025. InMode returned over $285 million to shareholders through share repurchases, representing about 19% of its share capital. The company ended the year with a strong balance sheet, holding $596.5 million in cash and equivalents. However, the macroeconomic environment remains challenging with no immediate signs of improvement.
Product StageCustomers
growth-negative
/PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial...
InMode Ltd., a global provider of medical technologies, reported a decline in its financial performance for the fourth quarter and full year of 2024. The company experienced a 23% decrease in quarterly revenues compared to the same period in 2023, with full-year revenues dropping by 20%. Despite these challenges, InMode returned $285.4 million to shareholders through share repurchases. The company plans to launch new platforms in 2025 to target the medical aesthetic and wellness markets. InModes management remains optimistic about future growth, supported by a strong balance sheet and ongoing innovation efforts.
growth-positive
InMode: Q4 Earnings Snapshot
InMode Ltd., a company based in Yokneam, Israel, reported its fourth-quarter earnings of $82.8 million, translating to a profit of $1.14 per share. Adjusted earnings were 42 cents per share. The company, which specializes in cosmetic surgery devices, posted a revenue of $97.9 million for the quarter. For the entire year, InMode reported a profit of $181.3 million, or $2.25 per share, with a total revenue of $394.8 million. The company forecasts full-year earnings to be between $1.95 and $1.99 per share, with revenue expected to range from $395 million to $405 million.
growth-negative
InMode Reports Fourth Quarter and Full Year 2024 Financial Results; Board of Directors Has Approved a New Share Repurchase Program
InMode Ltd., a leading provider of medical technologies, reported its financial results for Q4 and the full year 2024. The company experienced a decline in revenues, with Q4 revenues at $97.9 million, down from $126.8 million in the same quarter of 2023. Full-year revenues also decreased by 20% to $394.8 million. Despite these challenges, InMode returned $285.4 million to shareholders through share repurchases. The company is facing headwinds in the aesthetics industry and broader macroeconomic challenges. However, it remains committed to innovation, with new platforms like Ignite and OptimasMAX in early revenue stages and plans to launch additional platforms in 2025.
Product StageCustomers
growth-positive
/PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial...
InMode Ltd., a global leader in innovative medical technologies, announced that its Chief Financial Officer, Yair Malca, will host investor meetings at the BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference in Snowbird, Utah, on February 12, 2025. InMode specializes in developing, manufacturing, and marketing devices that utilize novel radiofrequency technology, aiming to enable new surgical procedures and improve existing treatments. The company offers a comprehensive line of products across various medical fields, including plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology.
growth-positive
InMode to Participate in the BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference
InMode Ltd., a global provider of innovative medical technologies, announced that its Chief Financial Officer, Yair Malca, will host investor meetings at the BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference in Snowbird, Utah, on February 12, 2025. InMode specializes in developing, manufacturing, and marketing devices that utilize novel radiofrequency technology, which is used in various medical fields such as plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. The company aims to enable new surgical procedures and improve existing treatments through its minimally invasive RF technologies. Interested investors are encouraged to contact their BTIG salesperson to schedule a meeting.
growth-negative
Do Options Traders Know Something About InMode (INMD) Stock We Don't?
The article discusses the recent high implied volatility in the options market for InMode Ltd., indicating potential significant stock movement. InMode is currently ranked as a Zacks Rank #4 (Sell) in the Medical - Products industry. Over the past 60 days, no analysts have increased their earnings estimates for the current quarter, while one analyst has revised the estimate downward. This has led to a decrease in the Zacks Consensus Estimate for the current quarter from 58 cents per share to 50 cents. The high implied volatility suggests that options traders are expecting a significant move in InModes stock, which could be a trade opportunity for seasoned traders.
growth-negative
InMode (NASDAQ:INMD) earnings and shareholder returns have been trending downwards for the last three years, but the stock rallies 5.1% this past week
InMode Ltd. has experienced a significant decline in its share price over the past three years, with a 62% drop, and a 27% decrease in the last year alone. Despite a recent 5.1% bounce in the share price, the company continues to face challenges, as evidenced by a compound annual decline in earnings per share (EPS) of 0.9% over the same period. This decline in EPS has likely contributed to the negative market sentiment, reflected in the companys current price-to-earnings (P/E) ratio of 9.25. While the broader market has gained 26% in the last year, InModes performance remains disappointing, prompting investors to seek improvements in fundamental business metrics before considering investment.
Neutral
InMode to Report Fourth Quarter & Full Year 2024 and Hold Conference Call on February 4, 2025, Earlier than Originally Announced
InMode Ltd., a leading global provider of innovative medical technologies, has rescheduled its fourth quarter and full year 2024 earnings conference call to Tuesday, February 4, 2025, at 8:30 a.m. Eastern Standard Time. The call, originally set for February 6, will feature presentations from key management figures, including CEO Moshe Mizrahy, CFO Yair Malca, and CTO Dr. Michael Kreindel. The company plans to release its financial results before the Nasdaq market opens on the same day. Participants are encouraged to pre-register for the call to receive a unique dial-in for immediate access. The call will also be webcast live on InModes website, with a replay available until February 11, 2025.
Neutral
/PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it has adjusted the date for its...
InMode Ltd., a global provider of innovative medical technologies, has rescheduled its fourth quarter and full year 2024 earnings conference call to February 4, 2025. The call will feature presentations from key management figures and will discuss the companys financial results. InMode specializes in developing and marketing devices using novel radiofrequency technology for various medical fields. The company emphasizes its commitment to enhancing surgical procedures and treatments. The conference call will be webcast live, and a replay will be available on InModes website. The press release includes forward-looking statements about future financial performance, cautioning that actual results may differ due to various risks and uncertainties.
Neutral
/PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it has adjusted the date for its...
InMode Ltd., a global provider of innovative medical technologies, has rescheduled its fourth quarter and full year 2024 earnings conference call to February 4, 2025. The call was originally set for February 6, 2025. The company will release its financial results before the Nasdaq market opens on the same day. The conference call will feature presentations from key management figures, including the CEO, CFO, and CTO. InMode specializes in developing and marketing devices using novel radiofrequency technology for various medical fields. The company emphasizes its forward-looking statements and advises caution regarding future projections.
growth-negative
DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Immediately Execute Tender Offer followed by Share Buyback
DOMA Perpetual Capital Management LLC, a significant shareholder of InMode Ltd., has sent a letter to the companys Board of Directors urging immediate action to improve shareholder returns. The letter criticizes InMode for its low stock price and substantial cash reserves, suggesting a tender offer for 30% of the company and an additional 10% share buyback in 2025. DOMA argues that InModes current market capitalization is lower than its cash on hand and projected free cash flow, and calls for a reduction in cash reserves to restore investor confidence. The letter highlights the need for a more aggressive financial strategy to enhance shareholder value.
growth-negative
InMode to Report Fourth Quarter & Full Year 2024 Financial Results and Hold Conference Call on February 6, 2025, Expects Q4 Revenue Between $97.0M-$97.5M
InMode Ltd., a leading provider of innovative medical technologies, announced its expectations for the fourth quarter and full year 2024 financial results. The company anticipates revenue for Q4 2024 to be between $97.0 million and $97.5 million, and full-year revenue to range from $394.0 million to $394.5 million. Despite these figures, management acknowledges stronger-than-expected headwinds in the aesthetics industry, exacerbated by broader macroeconomic challenges. The company projects full-year 2025 revenue to be between $395 million and $405 million. A conference call to discuss these results is scheduled for February 6, 2025. The call will feature presentations from key executives, including the CEO, CFO, and CTO.
growth-positive
With 57% institutional ownership, InMode Ltd. (NASDAQ:INMD) is a favorite amongst the big guns
The article discusses the ownership structure of InMode Ltd., highlighting that institutional investors hold a significant portion of the companys shares, with the top 25 shareholders owning 46% of the business. BlackRock, Inc. is the largest shareholder with 7.7% of shares. The article suggests that institutional ownership is generally viewed positively as it indicates credibility in the investment community. However, it also warns that changes in institutional investor sentiment could lead to rapid stock price changes. The article emphasizes the importance of understanding shareholder groups and their potential impact on the companys stock performance.
growth-positive
Why Is InMode Ltd. (INMD) Among the Best Cosmetic Surgery and Aesthetics Stocks to Invest In Now?
The article discusses the position of InMode Ltd. within the cosmetic surgery and aesthetics market amidst changing consumer preferences due to economic uncertainty. A Bloomberg Intelligence poll highlights a shift in consumer spending, with a decline in demand for mainstream beauty products. Despite this, high-end products are performing better, and younger generations are more willing to spend on beauty. The medical aesthetics market, including neuromodulators and dermal fillers, is projected to grow significantly by 2025. Ulta CEO Dave Kimbell expresses confidence in adapting to these changes for long-term growth. The article suggests a positive outlook for InMode Ltd. as the market for medical aesthetics is expected to expand.
growth-negative
The Returns On Capital At InMode (NASDAQ:INMD) Don't Inspire Confidence
The article discusses the financial performance of InMode, particularly focusing on its Return on Capital Employed (ROCE). InModes ROCE has declined from 31% five years ago to 18% currently, despite the company employing more capital. This decline is concerning as it suggests a potential loss of competitive advantage or market share. The companys current ROCE is still above the industry average of 9.6%, but the downward trend and reduced returns on investment are worrisome. Long-term shareholders have seen a 13% depreciation in their investment over the past five years, indicating market dissatisfaction with these trends. The article suggests that while InModes current valuation might still be attractive, the underlying trends are not promising.
growth-positive
Is InMode Ltd. (NASDAQ:INMD) Trading At A 47% Discount?
The article discusses the valuation of InMode Ltd. using the Discounted Cash Flow (DCF) model, estimating its fair value at US$35.05 per share. This suggests that the current share price of US$18.49 is potentially 47% undervalued. Analysts have set a price target of US$21.33, which is 39% below the fair value estimate. The DCF model used is a 2-stage model, accounting for different growth rates in cash flows over a ten-year period. The analysis indicates that InModes future cash flows are expected to grow, albeit at a slowing rate. The article emphasizes the importance of considering future cash flows present value, highlighting the companys potential for growth.
growth-positive
We Think You Can Look Beyond InMode's (NASDAQ:INMD) Lackluster Earnings
The article discusses InMode Ltd.s recent earnings report, which initially appeared weak but upon closer analysis reveals a strong financial position. The companys accrual ratio of -0.15 indicates excellent cash conversion, with free cash flow of $161 million surpassing its statutory profit of $153.7 million. Despite a year-on-year drop in free cash flow and a decrease in EPS over the past twelve months, the analysis suggests that InModes earnings potential is robust. The article emphasizes the importance of considering both historical data and analyst forecasts to assess the companys future profitability.
growth-positive
InMode to Present at Upcoming Investor Conferences
InMode Ltd., a global provider of innovative medical technologies, announced its participation in several investor conferences scheduled for November and December. The company will be represented by its Chief Financial Officer, Yair Malca, and Chief Executive Officer, Moshe Mizrahy, at events including the UBS Global Healthcare Conference, Jefferies London Healthcare Conference, Canaccord Genuity MedTech Forum, and Mizuho Medical Device Summit. These conferences will feature in-person fireside chats and one-on-one meetings, providing InMode an opportunity to engage with investors and showcase its advancements in minimally invasive radiofrequency technologies. InModes participation in these events highlights its commitment to expanding its presence in the medical technology sector.
growth-positive
InMode Third Quarter 2024 Earnings: Beats Expectations
InMode reported a revenue of $130.2 million for the third quarter of 2023, marking a 5.8% increase from the previous quarter. The net income rose by 9.6% to $51.0 million, and the profit margin improved to 39%. Earnings per share (EPS) increased to $0.66, surpassing analyst estimates by 17%. Despite these positive financial results, the companys shares have decreased by 2.7% over the past week. Looking forward, InModes revenue is expected to grow at an average rate of 5.9% annually over the next three years, which is below the 8.3% growth forecast for the US Medical Equipment industry. The article provides an analysis of InModes balance sheet and emphasizes the importance of considering a companys financial health.
growth-negative
InMode Ltd (INMD) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic Adjustments
InMode Ltd reported its Q3 2024 financial results, showing total revenue of $130.2 million and a strong GAAP gross margin of 82%. Despite a robust balance sheet with $684.9 million in cash and equivalents, the company faced several challenges. International sales decreased by 19% year-over-year, and macroeconomic factors like high interest rates negatively impacted sales, leading to a revision of the full-year guidance. The company launched two new platforms, IgniteRF and Optimus Max, which received early endorsements. However, the ongoing war in Israel increased manufacturing costs, affecting gross margins. In response to unsatisfactory results, InMode Ltd reorganized its corporate structure, including management changes in the US, UK, Spain, and France.
Management Changes
growth-negative
InMode Sees Revenue Growth Amidst Challenges in Q3 2024
InMode Ltd. reported a 5.8% increase in third-quarter 2024 revenues, totaling $130.2 million. Despite this growth, the company has adjusted its full-year revenue guidance down to between $410 million and $420 million, indicating a cautious outlook due to decreased demand for consumables and operational challenges stemming from macroeconomic conditions and recent management changes. Nevertheless, InMode maintains a robust cash position of $684.9 million, and its net income rose to $51.0 million, or $0.65 per diluted share, compared to the same quarter last year.
Management Changes
Q3 2024 Inmode Ltd Earnings Call
growth-positive
InMode: Q3 Earnings Snapshot
InMode Ltd., a company based in Yokneam, Israel, reported a net income of $51 million for its third quarter. The companys earnings per share were 65 cents, or 70 cents when adjusted for stock option expenses. InMode, which specializes in cosmetic surgery devices, achieved a revenue of $130.2 million during this period. The company has projected its full-year earnings to be between $1.92 and $1.96 per share, with anticipated revenue ranging from $410 million to $420 million. This financial performance indicates a positive growth trajectory for InMode.
growth-negative
InMode (INMD) Q3 2024 Earnings Call Transcript
InModes Q3 2024 earnings call highlighted a challenging quarter impacted by macroeconomic headwinds, leading to a revision of the full-year guidance. The company reported $130.2 million in revenue, with $31.9 million from pre-orders. Despite the introduction of new platforms, IgniteRF and OptimasMAX, sales were lower than expected due to decreased demand for minimally invasive treatments and a slowdown in platform sales. Management changes were made in the U.S., U.K., Spain, and France to better align with market needs. The company is facing challenges due to the ongoing war in Israel, affecting manufacturing costs and operations.
Management Changes
growth-positive
InMode (INMD) Q3 Earnings and Revenues Beat Estimates
InMode reported quarterly earnings of $0.70 per share, surpassing the Zacks Consensus Estimate of $0.57 per share, marking an earnings surprise of 22.81%. The company also reported revenues of $130.23 million, slightly exceeding the consensus estimate. Despite these positive results, InMode shares have decreased by about 19.5% since the beginning of the year, underperforming the S&P 500s gain of 22.3%. The companys earnings outlook remains mixed, with a Zacks Rank of #3 (Hold), indicating that the stock is expected to perform in line with the market in the near future. Investors are advised to monitor earnings estimate revisions closely, as they have a strong correlation with stock movements.
growth-negative
InMode Reports Third Quarter 2024 Financial Results; Quarterly GAAP Revenue of $130.2 Million (which consists of $98.3 million of net sales in Q3 and $31.9 million of pre-orders from the first half of 2024)
InMode Ltd., a leading global provider of innovative medical technologies, announced its financial results for the third quarter of 2024. The company reported GAAP revenue of $130.2 million, a 5.8% increase from the same quarter in 2023. However, revenue from consumables and services decreased by 11% compared to the previous year. The companys full-year revenue guidance was revised downward to $410-$420 million from the previous $430-$440 million. InModes CEO, Moshe Mizrahy, cited macroeconomic conditions and production line adjustments as challenges, but expressed confidence in recent management changes to align operations with strategic goals. The company holds a cash position of $684.9 million.
Management Changes
growth-positive
/PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, has been granted a preliminary injunction by the U.S....
InMode Ltd., a global provider of medical technologies, has been granted a preliminary injunction by the U.S. District Court for the Central District of California against sellers involved in the unlawful counterfeit sales of its Morpheus8 radiofrequency devices and accessories. The courts decision, issued on September 3, 2024, includes a Temporary Restraining Order (TRO) and asset freeze against the sellers. InModes CEO, Moshe Mizrahy, emphasized the companys commitment to public safety and its zero-tolerance policy for dishonest business practices. The legal action aims to protect InModes trademarks and prevent counterfeit products from being used in medical procedures. InMode continues to pursue enforcement against counterfeit sellers to ensure patients receive genuine products.
growth-positive
InMode Granted Preliminary Injunction Against Online Sellers Prohibiting Counterfeit Sales of Morpheus8 Radiofrequency Devices and Cartridge Accessories
InMode Ltd., a leading provider of medical technologies, has been granted a preliminary injunction by the U.S. District Court for the Central District of California against sellers of counterfeit Morpheus8 devices. The court order, issued on September 3, 2024, freezes assets and account listings of those involved in the sale of counterfeit goods. This legal action underscores InModes commitment to protecting its trademarks and ensuring public safety. The company emphasizes its zero-tolerance policy towards dishonest practices and will continue to pursue enforcement against counterfeit sellers. InModes efforts aim to prevent adverse reactions caused by counterfeit products and ensure patients receive genuine devices.
growth-negative
Earnings Preview: InMode (INMD) Q3 Earnings Expected to Decline
InMode is expected to report its earnings for the quarter ended September 2024 on October 30, 2024. Wall Street anticipates a year-over-year decline in earnings despite higher revenues. The company is projected to post quarterly earnings of $0.57 per share, a decrease of 6.6% from the previous year, with revenues expected to rise by 5.6% to $130 million. Analysts have revised the consensus EPS estimate 20.31% lower over the past 30 days. The Zacks Earnings ESP model suggests that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a strong Zacks Rank. The outcome of the earnings report could significantly impact InModes stock price, depending on whether the actual results meet or exceed expectations.
growth-positive
Is InMode (INMD) a Great Value Stock Right Now?
The article discusses InMode (INMD), a company currently holding a Zacks Rank of #2 (Buy) and a Value grade of A. InMode is highlighted as a strong value stock, with a P/E ratio of 7.86 compared to its industrys average of 21.99, and a P/B ratio of 1.81 compared to the industrys average of 5.28. These metrics suggest that the stock is undervalued. The article emphasizes the strength of InModes earnings outlook and its potential as an impressive value stock. The Zacks Rank system and Style Scores are used to identify stocks with specific traits, focusing on value investing strategies.
growth-negative
InMode price target lowered to $27 from $29 at Barclays
Barclays analyst Matt Miksic has adjusted the price target for InMode, lowering it from $29 to $27, while maintaining an Overweight rating. InModes preliminary Q3 sales exceeded consensus expectations, clearing back-orders of new products. However, management considered the results to be in line with internal objectives and typical Q3 seasonality. The company reported Q3 revenue between $130M and $130.1M, surpassing the consensus of $118.08M. Despite this, InMode has revised its FY24 revenue forecast downwards to $410M-$420M from $430M-$440M. The article highlights InModes restructuring efforts amidst global expansion.
Customers
growth-negative
InMode to Report Third Quarter 2024 Financial Results and Hold Conference Call on October 30, 2024
InMode Ltd., a global provider of medical technologies, announced its expected financial results for the third quarter of 2024. The company anticipates revenue between $130.0 million and $130.1 million, including $31.9 million from pre-orders. However, it has revised its full-year 2024 revenue guidance down to $410 million-$420 million from the previous $430 million-$440 million. The company is prioritizing the safety of its employees in Israel and considering relocating some production activities. InMode has fulfilled all pre-orders by the end of the third quarter. The company will host a conference call on October 30, 2024, to discuss these results. The announcement reflects challenges in the aesthetics industry and macroeconomic factors affecting the companys performance.
growth-negative
InMode Ltd (INMD) Q2 2024 Earnings Call Highlights: Navigating Challenges with New Innovations
InMode Ltd reported its Q2 2024 earnings, revealing a challenging quarter with a significant decline in demand for its treatments, particularly in the US market. The company experienced a 17% decrease in international sales and a 30% drop in disposable sales in the US. Consequently, InMode lowered its full-year 2024 revenue guidance from $485 million-$495 million to $430 million-$440 million. Despite these challenges, the company maintains a strong balance sheet with $729.2 million in cash and cash equivalents and completed a share repurchase program, acquiring 8.37 million shares. InMode also launched two new platforms, IgniteRF and Optimus Max, which are expected to contribute to future growth. The company continues to invest in R&D to develop advanced technologies for medical professionals.
Customers
growth-negative
InMode Restructures Amidst Global Expansion
InMode Ltd., a prominent player in medical technology, is undergoing a major reorganization aimed at aligning with its global expansion and entry into new markets, particularly the wellness sector. This restructuring has resulted in the departure of key North American executives, including the President of North America, the Chief Medical Officer, and the VP of Sales USA. The company plans to introduce new platforms and adapt its leadership structure by dividing the role of President of North America to better suit its evolving business landscape.
Management Changes
growth-positive
InMode Announces Departures of President of North America, Chief Medical Officer and VP of Sales USA as Part of a Global Reorganization Strategy
InMode Ltd., a global provider of innovative medical technologies, announced the departure of three key executives from its North American operations: Shakil Lakhani, President of North America, Dr. Spero Theodorou, Chief Medical Officer, and Dan Wilson, VP of Sales USA. These changes are part of a broader reorganization strategy aimed at optimizing the companys structure to support its global expansion and entry into new business verticals. The role of President of North America will be divided into separate roles to better manage growth. CEO Moshe Mizrahy emphasized that this reorganization is designed to enhance operational efficiency and build a robust infrastructure for future growth.
Management Changes
growth-positive
InMode Ltd.'s (NASDAQ:INMD) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
InModes stock has risen by 3.3% over the past week, driven by strong financials, particularly a high Return on Equity (ROE) of 20%. This ROE is significantly higher than the industry average of 11%, contributing to a notable 26% net income growth over the past five years. The company reinvests all its profits back into the business, which has fueled its earnings growth. However, analysts forecast a potential slowdown in earnings growth. The article emphasizes the importance of ROE and profit retention in assessing a companys growth potential.
growth-positive
/PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies today announced the departure of Shakil Lakhani,...
InMode Ltd., a leading global provider of innovative medical technologies, announced significant management changes, including the departure of Shakil Lakhani, President of North America, effective September 30, 2024. This follows the exits of Dr. Spero Theodorou, Chief Medical Officer, and Dan Wilson, VP of Sales USA. Additionally, InMode has restructured management teams in its European subsidiaries, including InMode UK, InMode Iberia, and InMode France. These changes are part of InModes strategy to optimize its structure for global expansion and entry into new business verticals. The role of President of North America will be divided into separate roles to better manage growth. CEO Moshe Mizrahy emphasized that these changes aim to enhance operational efficiency and support future growth.
Management Changes
growth-positive
Should Value Investors Buy InMode (INMD) Stock?
The article from Zacks Investment Research highlights InMode (INMD) as a strong value stock, emphasizing its high Zacks Rank of #1 (Strong Buy) and an A grade in the Value category. The stocks current P/E ratio is 8.15, significantly lower than the industry average of 22.12, indicating it may be undervalued. Additionally, InModes P/B ratio of 1.86 and P/CF ratio of 9.54 are also favorable compared to industry averages. These metrics suggest that InMode is an attractive investment option for value investors. The article encourages readers to consider InMode as a potential addition to their portfolios.
growth-positive
InMode (INMD): Among the Worst Middle East and Africa Stocks to Buy Now
InMode (NASDAQ:INMD), an Israeli company specializing in medical technologies, has been highlighted as one of the worst Middle East and Africa stocks to buy according to short sellers. Despite this, the company has received FDA 510(k) clearance for its Morpheus8 technology, which is expected to drive higher adoption and boost earnings. InModes strategy includes leveraging new systems like Optimus Max and IgniteRF, combating counterfeit products, and expanding its international sales network. The company is trading at a significant discount to the sector median, and 14 hedge funds, including Renaissance Technologies, have maintained a bullish sentiment on the stock.
CustomersInvestment
growth-positive
InMode Announces Share Repurchase Program of Up to 7.68 Million Shares
InMode Ltd., a global provider of innovative medical technologies, announced that its Board of Directors has approved a share repurchase program of up to 7.68 million ordinary shares. This decision follows the completion of a previous buyback program and reflects the companys confidence in its long-term outlook. The repurchases will be funded with available cash, and the company believes there will be no tax implications. InMode continues to be profitable and generate cash despite challenging economic conditions. The company specializes in minimally-invasive RF technologies for various medical fields.
Investment
growth-positive
/PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that its Board of Directors has...
InMode Ltd., a global provider of innovative medical technologies, announced that its Board of Directors has approved a new share repurchase program for up to 7.68 million ordinary shares. This decision follows the completion of a previous buyback program and reflects the companys confidence in its long-term outlook. The repurchases will be funded with available cash, and the company expects no tax implications from the program. InMode continues to be profitable and generate cash despite challenging economic conditions, driven by its strong cash position and low current valuation.
Investment
growth-positive
Are Investors Undervaluing InMode (INMD) Right Now?
InMode (INMD) is currently highlighted as a strong value stock by Zacks Investment Research, holding a Zacks Rank of #1 (Strong Buy) and a Value grade of A. The companys P/E ratio of 7.73 and P/B ratio of 1.75 are significantly lower than the industry averages, indicating that the stock is undervalued. Over the past year, INMDs Forward P/E has ranged from 6.86 to 13.19, and its P/B has ranged from 1.73 to 4.91. These metrics, combined with a positive earnings outlook, suggest that INMD is an impressive value stock at the moment.
growth-positive
/PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial...
InMode Ltd., a leading provider of innovative medical technologies, announced that its Chief Financial Officer, Yair Malca, will present at the 2024 Baird Global Healthcare Conference in New York on September 10, 2024. The presentation will be moderated by Jeff Johnson, Senior Research Analyst, and will include a live webcast. InMode will also hold one-on-one investor meetings on the same day. The company specializes in developing and marketing devices using novel radiofrequency technology for various medical fields, including plastic surgery and dermatology.
Investment
growth-positive
InMode to Present at 2024 Baird Global Healthcare Conference
InMode Ltd., a leading global provider of innovative medical technologies, announced that its Chief Financial Officer, Yair Malca, will present at the 2024 Baird Global Healthcare Conference in New York on September 10, 2024. The presentation will be moderated by Jeff Johnson, Senior Research Analyst, and will be available via live webcast. InMode will also hold one-on-one investor meetings on the same day. The company specializes in developing and marketing devices using novel radiofrequency technology for various medical fields.
Investment
growth-positive
InMode (INMD): The Best Middle East and Africa Stocks to Buy According to Analysts?
InMode (NASDAQ:INMD), an Israeli company specializing in advanced medical technologies, is highlighted as a strong investment despite recent challenges. The companys stock was negatively impacted by geopolitical tensions and seasonality concerns, but it remains promising due to its innovative radio-frequency technology and strong financials. InMode reported a 36.5% year-over-year revenue decrease in Q2 2023 but maintained high gross margins. The company secured FDA clearance for its Morpheus8 technology and introduced new platforms, which are expected to boost earnings. InMode is also expanding its international sales and combating counterfeit products. Renaissance Technologies is the largest shareholder, with a stake worth $37.72 million.
Investment
growth-negative
InMode Ltd. (INMD): Challenges and Insights in the Beauty Industry
The article discusses the potential of various industries to change the world and their impact on the stock market. It highlights the transformative power of technologies like personal computing, the internet, and artificial intelligence. It also mentions the potential of quantum computing, nuclear energy, and robotics. The article then discusses the performance of InMode Ltd., an Israeli beauty company, whose shares have lost almost 62% of their value over the past twelve months. The companys falling returns suggest a lower market for its products, leading to its elimination from the list of stocks that will change the world.
Customers
growth-positive
Why Are Analysts Bullish on InMode Ltd. (INMD) Right Now?
InMode Ltd. is a company that develops, manufactures, and markets minimally invasive medical devices for cosmetic purposes. The global cosmetic surgery market is expected to grow from $59.77 billion in 2024 to $81.66 billion by 2032. InMode Ltd. is considered one of the best cosmetic surgery and aesthetics stocks to buy now, with a unique technological advantage that sets it up for future growth. However, the company has been downgraded from Buy to Hold by Jefferies due to wider economic issues and worries about the impact on the aesthetics market.
CustomersInvestment
growth-negative
Some Investors May Be Willing To Look Past InMode's (NASDAQ:INMD) Soft Earnings
InMode Ltd. posted weak earnings, disappointing investors. However, analysis of the companys income statement remains optimistic. The companys accrual ratio indicates strong conversion of profit to free cash flow, suggesting that its statutory profit may understate its earnings potential. Despite a drop in free cash flow year on year, InModes earnings per share have grown at 7.4% per year over the last three years. Analysts forecasts for the companys future profitability are available for viewing.
Investment
growth-positive
InMode to Present at Upcoming Investor Conferences
InMode Ltd., a global provider of innovative medical technologies, has announced its participation in several investor conferences and events in August. The companys CEO, Moshe Mizrahy, and CFO, Yair Malca, will be presenters at these events. The events will include virtual one-on-one meetings and in-person fireside chats. A live webcast of the presentation can also be accessed. InMode develops, manufactures, and markets devices harnessing novel radiofrequency technology for various medical fields.
Investment
growth-negative
InMode Ltd. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
InMode Ltd.s latest Q2 report shows earnings falling short of analyst estimates, with revenues of $86m missing by 19% and EPS of $0.28 falling short by 13%. Analysts are now predicting revenues of $442.8m in 2024, reflecting a 6.3% improvement compared to the last 12 months. However, EPS is expected to dip 2.5% to $1.72 in the same period. The analysts made no major changes to their price target of $21.20, suggesting the downgrades are not expected to have a long-term impact on InModes valuation.
Investment
growth-negative
InMode (INMD) Q2 2024 Earnings Call Transcript
InMode reported its Q2 2024 earnings, revealing a challenging quarter with a significant decrease in demand for treatment, primarily in the U.S. The company launched two new advanced platforms, IgniteRF and Optimus Max, and has begun deliveries with strong demand. Despite the challenging quarter, InMode generated $86.4 million in Q2 2024, with pro forma revenue at $102.6 million. The company also announced management changes with Dr. Eran Krieger being introduced as the new medical director and VP of medical affairs.
Management ChangesExpand
growth-positive
InMode: Q2 Earnings Snapshot
InMode Ltd., a company based in Yokneam, Israel, reported a net income of $23.8 million for its second quarter. The company, which manufactures cosmetic surgery devices, also reported a profit of 28 cents per share. When adjusted for stock option expense, the earnings were 34 cents per share. The company posted a revenue of $86.4 million for the period.
Investment
growth-negative
InMode Reports Second Quarter 2024 Financial Results; Quarterly Revenue of $86.4M Represents 36.5% Year-Over-Year Decrease; Pro Forma Revenue (including new platform pre-orders not yet delivered) of $102.6M
InMode Ltd., a global provider of innovative medical technologies, has reported its Q2 2024 financial results, showing a decrease in revenue. The companys GAAP revenue was $86.4 million, a decrease of 36.5% compared to Q2 2023. The majority of its quarterly revenues came from its proprietary surgical technology platforms. The company also reported a GAAP net income of $23.8 million, compared to $55.7 million in Q2 2023. Despite the challenging quarter, the company remains optimistic about its new platforms, Ignite and Optimus Max, which it believes will be growth catalysts.
Customers
Growth-Negative
InMode (INMD) Q2 Earnings and Revenues Top Estimates
InMode reported its quarterly earnings at $0.34 per share, surpassing the Zacks Consensus Estimate of $0.30 per share. However, this is a decrease from the earnings of $0.72 per share a year ago. The company, which manufactures cosmetic surgery devices, reported revenues of $86.45 million for the quarter ended June 2024, a decrease from the year-ago revenues of $136.08 million. Despite surpassing consensus estimates four times in the last four quarters, InMode shares have lost about 18.5% since the beginning of the year. The companys future performance is expected to depend on managements commentary on the earnings call.
Customers
growth-positive
Investing in InMode (NASDAQ:INMD) five years ago would have delivered you a 167% gain
InMode Ltd. has seen its share price increase by 167% over the past five years, with a 3.0% increase in the last week alone. The companys compound earnings per share (EPS) growth has been 35% per year, higher than the 22% average annual increase in the share price. Despite this, the market appears apprehensive, as indicated by the relatively low P/E ratio of 8.47. While InModes shareholders lost 58% in the last year, long-term investors have made a 22% return each year over five years.
Public Trading
growth-positive
InMode Introduces IgniteRF The Complete Minimally Invasive Soft Tissue Contraction Platform
InMode Ltd., a global provider of innovative medical technologies, has announced the introduction of IgniteRF, a minimally invasive workstation that includes nine technologies for soft tissue contraction across multiple tissue depths. The IgniteRF platform, along with the BodyTite, FaceTite, Morpheus8, and QuantumRF family of products, offers a comprehensive suite of radiofrequency solutions for various aesthetic and surgical needs. QuantumRF is a new technology that deploys fractionated radiofrequency to maximal depths. The technology is considered the gold standard in skin contraction within the aesthetics industry due to its effectiveness, safety, and minimally or non-invasive nature.
Expand
growth-positive
Owens & Minor (OMI) Earnings Expected to Grow: Should You Buy?
Owens & Minor (OMI) is expected to report a year-over-year increase in earnings on higher revenues for the quarter ended June 2024. The earnings report, which is expected to be released on August 2, 2024, might help the stock move higher if the key numbers are better than expectations. The medical supply distributor is expected to post quarterly earnings of $0.33 per share, which represents a year-over-year change of +83.3%. Revenues are expected to be $2.65 billion, up 3.4% from the year-ago quarter.
InvestmentPublic Trading
growth-negative
DOMA Perpetual Sends Letter to the Board of Directors of InMode Urging the Execution of a 40% Tender Offer
DOMA Perpetual Capital Management LLC, one of the largest shareholders of InMode, has sent a letter to the Board of Directors of InMode urging them to execute a 40% tender offer of the stock. DOMA expressed concerns about InModes capital allocation strategy and the companys declining stock price. DOMA believes that the Board needs a strong independent voice that will advocate for the interests of the companys shareholders. The letter also criticizes the Boards failure to make attractive acquisitions and its inefficient and ineffective capital allocation strategy.
Management ChangesInvestment
growth-negative
Analysts Estimate InMode (INMD) to Report a Decline in Earnings: What to Look Out for
InMode is expected to report a year-over-year decline in earnings on lower revenues for the quarter ended June 2024. The stock might move higher if the key numbers top expectations in the upcoming earnings report, expected to be released on August 1. However, if they miss, the stock may move lower. The company is expected to post quarterly earnings of $0.30 per share, representing a year-over-year change of -58.3%. Revenues are expected to be $86.2 million, down 36.7% from the year-ago quarter.
Investment
growth-positive
Morpheus8 Secures First and Only FDA Clearance for Soft Tissue Contraction for Fractional Radiofrequency Microneedling
InMode Ltd., a global provider of innovative medical technologies, has received an additional FDA 510(k) clearance for its Morpheus8 technology. This technology is the first fractional radiofrequency (FRF) microneedling technology cleared for contraction of soft tissue. The FDA has also cleared the use of Morpheus8 Applicators for dermatologic skin procedures where coagulation/contraction of soft tissue or hemostasis is needed. This clearance coincides with the launch of InModes new IgniteRF and OptimasMAX platforms, which include the Morpheus8 family of handpieces.
CustomersExpand
growth-negative
InMode to Report Second Quarter 2024 Financial Results and Hold Conference Call on Aug. 1, 2024
InMode Ltd., a global provider of innovative medical technologies, is set to release its financial results for Q2 2024 before the Nasdaq market opens on August 1, 2024. Preliminary results suggest that Q2 revenue will be between $86.2 million and $86.3 million, and pro-forma revenue (including pre-orders of new platforms not yet delivered) will be between $102.4 million and $102.5 million. However, the company has decreased its FY 2024 guidance to $430 million-$440 million from the previous guidance of $485 million to $495 million.
Customers
growth-positive
3 MedTech Stocks to Buy for Healthy Gains
The article discusses the potential of the MedTech sector, which is expected to reach a valuation of $776.47 billion by 2033, implying a compound annual growth rate (CAGR) of 4.4%. It highlights three companies - Abbott Laboratories, InMode, and Outset Medical - as promising investment opportunities. Abbott Laboratories is a trusted name in the sector, offering a range of healthcare products and generic pharmaceuticals. InMode, based in Israel, designs, develops, manufactures, and markets minimally invasive aesthetic medical products. Outset Medical, based in California, develops a compact dialysis system called Tablo.
InvestmentCustomers
growth-positive
InMode Ltd. (NASDAQ:INMD) is favoured by institutional owners who hold 67% of the company
InMode Ltd. has a significant portion of its shares, around 67%, held by institutions, with the largest shareholder being BlackRock, Inc. owning 7.4%. This institutional ownership could make the companys stock price vulnerable to their trading decisions. However, it also indicates a vote of confidence in the companys future. The companys CEO Moshe Mizrahy directly holds 2.4% of the total shares outstanding. The general public holds a 23% stake in InMode. The article suggests that understanding the ownership structure can provide insights into the companys performance and future.
Investment
growth-negative
Returns On Capital At InMode (NASDAQ:INMD) Paint A Concerning Picture
InModes return on capital employed (ROCE) has fallen from 56% to 21% over the last five years, indicating a negative trend. Despite reinvesting funds back into the business for growth, sales have not significantly increased. The companys current liabilities have decreased to 7.3% of total assets, which could partly explain why the ROCE has dropped. The stock has declined 57% over the last three years, suggesting investors may not be optimistic about the trend improving.
Investment
Growth-Positive
InMode to Present at Jefferies Healthcare Conference
InMode Ltd., a global provider of innovative medical technologies, has announced that its Chief Financial Officer, Yair Malca, and Chief Medical Officer, Spero Theodorou MD, will present at the Jefferies Healthcare Conference in New York on June 5, 2024. The presentation will be moderated by Matt Taylor, Managing Director, Senior Healthcare Analyst. InMode will also hold one-on-one investor meetings on the same day. The company develops, manufactures, and markets devices using novel radiofrequency technology for various medical fields.
Investment
growth-positive
InMode Announces P1 Offshore Racing Partnership with Female Driver Victoria Rand
InMode Ltd., a global provider of innovative medical technologies, has become the first aesthetic company to partner with P1 Offshore Racing and sponsor the only female driver, Victoria Rand. This partnership is a historic step in motorsports and reflects InModes dedication to empowering women. Victoria Rand, from Denmark, has a deep-rooted lineage in racing and is known for her passion for speed and competition. InModes Chief Medical Officer, Spero Theodorou, expressed excitement about supporting a female driver who is an inspiration for women everywhere.
Partners
growth-positive
InMode Announces P1 Offshore Racing Partnership with Female Driver Victoria Rand
InMode Ltd., a global provider of innovative medical technologies, has partnered with P1 Offshore Racing and is sponsoring Victoria Rand, the only female driver in Class 1. This partnership is a historic step in motorsports and reflects InModes dedication to empowering women. Victoria Rand, from Denmark, has a deep-rooted lineage in racing and is now aiming to conquer the waves as part of the Morpheus8 Offshore Race Team. InModes Chief Medical Officer, Spero Theodorou, expressed excitement about supporting a female driver who is a trailblazer and inspiration for women everywhere.
Partners
growth-negative
InMode Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
InMode Ltd. failed to meet expectations in its Q1 results, with revenues of $80m falling 12% below expectations and earnings per share of $0.28 missing estimates by 28%. Analysts have become more bearish following the results, with no changes to revenue forecasts but a significant cut to EPS estimates. The average price target fell 7.2% to $25.60. Analysts expect InModes revenue growth to slow down substantially, with revenues to the end of 2024 expected to display 5.3% growth on an annualised basis, compared to a historical growth rate of 29% over the past five years.
Customers
growth-negative
InMode Ltd. (NASDAQ:INMD) Q1 2024 Earnings Call Transcript
InMode Ltd. held its Q1 2024 earnings call, during which it reported a challenging macro environment and a slowdown throughout the first quarter. As a result, the company has decided to decrease its guidance for the year. Despite these challenges, InMode launched two new platforms, IgniteRF and Optimus Max, which accounted for 16% of sales in Q1. However, delivery was delayed due to ongoing construction of the manufacturing line. The companys Board of Directors has approved a third share repurchase program up to 8.37 million shares. InMode also welcomed Dr. Michael Anghel as the new Chairman of the Board.
Management ChangesInvestmentExpand
growth-negative
InMode Reports First Quarter 2024 Financial Results; Quarterly Revenue of $80.3M Represents 24% Year-Over-Year Decrease; Pro Forma Revenue (including new platform pre-orders not yet available) of $96M;
InMode Ltd., a global provider of innovative medical technologies, has reported a decrease in its Q1 2024 revenue, down 24% compared to Q1 2023. The company also announced a share repurchase program of up to 8.37 million shares and the appointment of a new Chairman of the Board, Dr. Michael Anghel, effective from July 25, 2024. Despite the decrease in revenue, the company reported record quarterly revenues from consumables and service of $22.5 million, up 13% compared to Q1 2023. The company also revised its full-year 2024 revenue guidance to $485 to $495 million, down from the previous guidance of $495 million to $505 million.
Management Changes
Growth-negative
InMode Shares Rise; Q1 Non-GAAP Earnings, Revenue Fall; 2024 Guidance Cut
The article reports on the US economy adding 175,000 jobs in April, which is fewer than expected. It also mentions that InModes shares have risen, despite the companys Q1 non-GAAP earnings and revenue falling. The company has also cut its 2024 guidance.
Management Changes
growth-negative
InMode (INMD) Q1 2024 Earnings Call Transcript
InMode reported its Q1 2024 earnings, revealing a slowdown in sales and a decrease in its guidance for the year. The company launched two new platforms, IgniteRF and Optimus Max, which accounted for 16% of sales in Q1. However, delivery was delayed due to ongoing construction of the manufacturing line. The company also announced a third share repurchase program and the appointment of Dr. Michael Anghel as the new chairman of the board. InMode is also dealing with the impact of the ongoing war in Israel, which has affected the assembly line of the new platforms and may delay delivery.
Management ChangesExpand
growth-negative
InMode (INMD) Q1 Earnings and Revenues Beat Estimates
InMode reported quarterly earnings of $0.45 per share, surpassing the Zacks Consensus Estimate of $0.40 per share. However, this is lower than the earnings of $0.52 per share a year ago. The company, which belongs to the Zacks Medical - Products industry, posted revenues of $80.28 million for the quarter ended March 2024, surpassing the Zacks Consensus Estimate by 0.23%. This is lower than the year-ago revenues of $106.07 million. InMode shares have lost about 22.5% since the beginning of the year. The companys future performance is expected to be influenced by the industry outlook and earnings expectations.
Public Trading
growth-negative
Earnings Preview: InMode (INMD) Q1 Earnings Expected to Decline
InMode is expected to report a year-over-year decline in earnings and lower revenues for the quarter ended March 2024. The earnings report, due to be released on May 2, 2024, could influence the companys stock price. The company is expected to post quarterly earnings of $0.40 per share, a year-over-year change of -23.1%, with revenues expected to be $80.1 million, down 24.5% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 19.36% lower over the last 30 days. The stock currently carries a Zacks Rank of #4.
Investment
Growth-Positive
Could The Market Be Wrong About InMode Ltd. (NASDAQ:INMD) Given Its Attractive Financial Prospects?
InModes share price has fallen by 25% over the last three months. However, the companys financial performance appears promising in the long term. The companys Return on Equity (ROE) is particularly noteworthy. The ROE for InMode is 25%, indicating that for every $1 worth of shareholders equity, the company generated $0.25 in profit. InModes net income growth over the past five years has been exceptional at 35%, significantly higher than the industry average of 14%. The company does not pay regular dividends, indicating that all profits are being reinvested into the business. Despite the positive performance, analysts predict a slowdown in the companys future earnings growth.
growth-negative
InMode Responds To BTL Petition for Inter Partes Review Of Patent InMode Is Asserting Against BTL
InMode Ltd., a global provider of innovative medical technologies, has responded to a petition filed by BTL Industries, Inc. to the U.S. Patent & Trademark Office. BTL is asking the USPTO to conduct an Inter Partes Review of InModes U.S. Patent No. 8,961,511. This comes after InMode sued BTL, alleging that BTLs UltraFemme 360 and EmFemme 360 products infringe on the patent. InModes Chief Technology Officer, Dr. Michael Kreindel, stated that they look forward to defending the validity of their patent before the USPTO and continuing their case against BTL in the California district court.
CustomersPartners
growth-negative
InMode to Report First Quarter 2024 Financial Results and Hold Conference Call May 2, 2024
InMode Ltd., a global provider of innovative medical technologies, has announced preliminary financial results for Q1 2024, with revenue expected to be between $80.0M-$80.1M and pro forma revenue (including new platform pre-orders) between $95.7M-$95.8M. However, the company has decreased its FY 2024 guidance to $485M-$495M. The company is in a transition phase due to the initial launch of its new platforms in 2024, and the esthetics industry is facing challenges due to the macro-economic environment.
Customers
Growth-Negative
InMode (INMD) Ascends But Remains Behind Market: Some Facts to Note
InMode (INMD) closed the latest trading day at $20.62, indicating a slight increase from the previous session. However, the stock fell short of the S&P 500, which registered a gain of 0.11% for the day. In the past month, shares of the maker of cosmetic surgery devices had lost 10.16%. The upcoming earnings release of InMode will be of great interest to investors. The company is forecasted to report an EPS of $0.53, showcasing a 1.92% upward movement from the corresponding quarter of the prior year. However, revenue is expected to be down 1.67% from the prior-year quarter.
growth-positive
InMode to Present at Upcoming Investor Conferences and Events
InMode Ltd., a global provider of innovative medical technologies, has announced its participation in several investor conferences and events in April and May. The companys presenters at these events will include CEO Moshe Mizrahy, CFO Yair Malca, and CMO Spero Theodorou. The events include the 23rd Annual Needham Virtual Healthcare Conference, the BNPP Exane 2nd Annual Aesthetics Day, and the Barclays West Coast Bus Trip.
Investment
Neutral
Is InMode (INMD) a Buy as Wall Street Analysts Look Optimistic?
InMode currently has an average brokerage recommendation (ABR) of 2.00, indicating a Buy status. However, the article suggests that investors should not solely rely on brokerage recommendations as they often have a vested interest in the stocks they cover, resulting in a strong positive bias. Instead, it recommends using tools like Zacks Rank, which categorizes stocks based on earnings estimate revisions, to validate investment decisions. The Zacks Consensus Estimate for InMode has remained unchanged over the past month at $2.56, resulting in a Zacks Rank #3 (Hold) for InMode.
Investment
growth-negative
InMode Ltd. (INMD) is Attracting Investor Attention: Here is What You Should Know
InMode, a maker of cosmetic surgery devices, has seen its shares return -5.8% over the past month, compared to the Zacks S&P 500 composites +3.3% change. The company is expected to post earnings of $0.53 per share for the current quarter, a change of +1.9% from the year-ago quarter. The consensus sales estimate for the current quarter is $104.3 million, a year-over-year change of -1.7%. InMode reported revenues of $126.78 million in the last reported quarter, a year-over-year change of -5.1%. The companys stock is currently graded B, indicating that it is trading at a discount to its peers.
Public Trading
growth-positive
Why InMode (INMD) Outpaced the Stock Market Today
InModes stock closed at $21.61 in the latest trading session, marking a 1.93% increase from the prior day. This performance was ahead of the S&P 500s daily gain of 0.11%. Despite losing 2.21% over the past month, investors are eagerly watching for the performance of InMode in its upcoming earnings disclosure. The company is predicted to post an EPS of $0.53, indicating a 1.92% growth compared to the equivalent quarter last year. The revenue is predicted to be $104.3 million, indicating a 1.67% decrease compared to the same quarter of the previous year.
Public Trading
growth-positive
14 Best Medical Device Stocks To Buy Now
The article discusses the growth and investment opportunities in the medical device industry, highlighting 14 companies as the best stocks to buy now. These include Abbott Laboratories, Thermo Fisher Scientific Inc., Johnson & Johnson, Inmode Ltd, Edwards Lifesciences Corporation, Veeva Systems Inc., Cardinal Health, Inc., Stryker Corporation, Medtronic plc, Illumina, Inc., and DexCom, Inc. The global medical devices market, valued at $570 billion in 2022, is projected to reach approximately $996.93 billion by 2032. The surge in demand for innovative therapies and ongoing technological advancements in medical devices are driving the growth of the market.
Investment
growth-negative
InMode (INMD) Stock Falls Amid Market Uptick: What Investors Need to Know
InMode (INMD) closed at $21.23 in the latest trading session, marking a -0.05% move from the previous day. This move lagged the S&P 500s daily gain of 0.32%. The companys shares had gained 1.92% in the past month. The investment community will be closely watching InModes upcoming earnings performance. The company is forecasted to report an EPS of $0.53, showcasing a 1.92% upward movement from the corresponding quarter of the prior year. The Zacks Consensus Estimates project earnings of $2.56 per share and a revenue of $500.8 million for the full year.
Public Trading
growth-negative
InMode Ltd. (INMD) Is a Trending Stock: Facts to Know Before Betting on It
InModes stock performance has been under scrutiny, with shares returning -9% over the past month. This is compared to the Zacks S&P 500 composites +3% change. InMode is expected to post earnings of $0.53 per share for the current quarter, a year-over-year change of +1.9%. The consensus sales estimate of $104.3 million for the current quarter points to a year-over-year change of -1.7%. InMode reported revenues of $126.78 million in the last reported quarter, a year-over-year change of -5.1%. The companys Zacks Rank is #3 (Hold), suggesting it may perform in line with the broader market in the near term.
Public Trading
Neutral
Brokers Suggest Investing in InMode (INMD): Read This Before Placing a Bet
InMode (INMD) currently has an average brokerage recommendation (ABR) of 2.00, indicating a Buy status. This is based on the recommendations made by six brokerage firms, with three being Strong Buy, representing 50% of all recommendations. However, the article suggests that investment decisions should not be solely based on this information due to the vested interest of brokerage firms in the stocks they cover, which often results in a strong positive bias. The article recommends using the Zacks Rank, a proprietary stock rating tool, to validate the ABR. The Zacks Rank for InMode is currently #3 (Hold).
Investment
Growth-Negative
Why InMode (INMD) Dipped More Than Broader Market Today
InModes stock closed at $20.91, marking a 1.97% decrease from the previous day. This lagged behind the S&P 500s 0.65% loss. Over the past month, the companys stock has dropped by 10.27%, underperforming the Medical sectors gain of 1.98% and the S&P 500s gain of 3.27%. In its upcoming earnings disclosure, InMode is projected to report earnings of $0.53 per share, representing a year-over-year growth of 1.92%. However, quarterly revenue is expected to be down 1.67% from the year-ago period. The company is currently a Zacks Rank #3 (Hold).
Public Trading
Growth-Positive
Should You Hold Inmode Ltd. (INMD)?
Wasatch Global Investors, an asset management company, has released its Q4 2023 investor letter, revealing a double-digit gain for its Wasatch Micro Cap Value Strategy. However, it trailed the benchmark Russell Microcap Index, which rose 16.06%. In 2023, the strategy appreciated and outperformed the benchmark’s 9.33% return. The letter also highlighted InMode Ltd., an Israeli company that develops aesthetic treatments. Despite a drop in stock due to an attack on Israel and a forecast of increased seasonality in InMode’s revenues and earnings, Wasatch still favours InMode due to its technological edge, strong balance sheet, and high gross margins.
Investment
growth-positive
Should You Hold InMode Ltd. (INMD)?
Investment management company Ave Maria recently released its “Ave Maria World Equity Fund” fourth quarter 2023 investor letter. The fund returned 13.99% in the fourth quarter and 24.96% for the full year. The fund featured stocks like InMode Ltd., a company that develops, manufactures, and markets minimally invasive aesthetic medical products. InMode Ltd. has a market capitalization of $1.815 billion. At the end of the fourth quarter, InMode Ltd. was held by 24 hedge fund portfolios.
Investment
growth-positive
InMode to Present at March Investor Conferences and Events
InMode Ltd., a global provider of innovative medical technologies, has announced its participation in several investor conferences and events in March. These include the Oppenheimer 34th Annual Healthcare MedTech & Services Conference, the 2024 Barclays Global Healthcare Conference, and the Jefferies Miami MedTech Doctor Summit. The companys CEO, CFO, and CMO will be presenting at these events. InMode develops, manufactures, and markets devices using novel radiofrequency technology for various medical fields.
Investment
growth-negative
Cathie Wood Was Buying These 11 Stocks for 2024
Cathie Woods ARK Investment Management has been under scrutiny following a loss of about $14.3 billion in shareholder value over the past decade. Despite this, ARK funds have not seen a mass investor exodus, possibly due to Woods investment philosophy which demands a five-year investment horizon. ARKs flagship ETF, ARK Innovation, rallied about 70% in 2023. Woods top holdings include Tesla, Block, and Shopify. However, she has been criticized for selling Nvidia in January 2023, just as the AI boom was taking off. This article also details 11 stocks that Wood was buying for 2024, including Nano-X Imaging, Pagaya Technologies, and Inmode.
InvestmentManagement Changes
Growth-negative
Is It Worth Investing in InMode (INMD) Based on Wall Street's Bullish Views?
The article discusses the reliability of brokerage recommendations for stocks, using InMode (INMD) as an example. InMode currently has an average brokerage recommendation (ABR) of 2.00, indicating a Buy status. However, the article warns that these recommendations may be biased due to the vested interests of brokerage firms. It suggests using tools like the Zacks Rank, which is based on earnings estimate revisions, to validate these recommendations. The Zacks Consensus Estimate for InMode has declined 0.4% over the past month, leading to a Zacks Rank #4 (Sell) for InMode.
Investment
growth-negative
InMode Ltd. (NASDAQ:INMD) Q4 2023 Earnings Call Transcript
InMode Ltd. reported its Q4 2023 earnings, beating expectations with a reported EPS of $0.71 against expectations of $0.68. However, the company experienced a 5% YoY decline in Q4 revenue, amounting to $126.8 million. Despite this, the companys full year revenue grew to a record of $492 million, an 8% increase compared to 2021. The company also introduced two new platforms, Envision and Define, and plans to launch two more in 2024. InMode is also establishing an approval program with financial institutions to improve and expedite the credit decision process.
CustomersManagement ChangesExpand
growth-negative
Q4 2023 Inmode Ltd Earnings Call
InMode Ltd held its Q4 and full year 2023 earnings conference call, discussing the companys performance and future projections. The company reported a 5% year-over-year decline in Q4 revenue, amounting to $126.8 million, but saw an 8% increase in full-year revenue to a record $492 million. InMode also reported challenges in the aesthetic industry and a slowdown in growth rates due to macroeconomic factors. However, the company plans to launch two new platforms in 2024 and is exploring potential M&A opportunities.
CustomersManagement ChangesInvestmentExpand
growth-positive
InMode Full Year 2023 Earnings: EPS Beats Expectations
InMode has reported its full year 2023 results, showing an increase in revenue, net income, profit margin, and EPS from the previous year. Revenue was in line with analyst estimates, while EPS surpassed estimates by 3.4%. The companys shares are down 5.4% from a week ago. Looking ahead, revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US.
Public Trading
growth-negative
InMode (INMD) Q4 2023 Earnings Call Transcript
InMode reported a 5% year-over-year decline in Q4 2023 revenue, amounting to $126.8 million. However, the companys full-year revenue grew to a record $492 million, reflecting an 8% increase compared to 2021. The company faced challenges in the aesthetic industry and revised its guidance for the first time due to the increased impact of the industry slowdown. InMode plans to launch two new platforms in 2024, offering significant improvements in technology and energy levels. The company also plans to establish approval programs with financial institutions to improve and expedite the credit decision process.
CustomersInvestmentExpand
growth-negative
Former Highflier InMode Crumbles As Interest Rates, Macro Weigh On Aesthetics Procedures
InModes stock fell by 8.5% due to high interest rates impacting the companys top line. The high rates deterred some doctors from purchasing surgical systems, leading to a slowdown in the number of procedures performed using InModes devices. Sales fell by 5% to $126.8 million, slightly above the companys preannouncement. The company also launched its ophthalmology system, Envision, in the US in the second quarter, which generated $30 million in sales in three quarters of 2023. For the year, InMode guided to $495 million to $505 million in sales and adjusted earnings of $2.53 to $2.57 per share.
Customers
growth-positive
InMode Reports Fourth Quarter and Full Year 2023 Financial Results; Quarterly Revenue of $126.8M and Record Full Year Revenue of $492M
InMode Ltd., a global provider of innovative medical technologies, has announced its financial results for Q4 and the full year of 2023. The company reported a quarterly revenue of $126.8 million and a full year revenue of $492 million, marking an 8% YoY increase. The companys GAAP net income for 2023 was $197.9 million, up from $161.5 million in 2022. InMode also reported an 18% increase in international revenues compared to 2022. The companys total cash position as of December 31, 2023, was $741.6 million.
Investment
growth-positive
Forget the "Magnificent Seven": These 2 Under-the-Radar Growth Stocks Are Better Bargains
The article discusses the rising interest in AI-related businesses, particularly in the stock market. It highlights two companies, TransMedics Group and InMode, that are not part of the Magnificent Seven AI stocks but are showing promising growth. TransMedics Group is improving the organ donation process in America with its FDA-approved Organ Care System (OCS) and has also acquired an aviation business for organ transport. InMode, a medical technology company, offers a range of devices for dermatologists and plastic surgeons. Despite facing some challenges, both companies are expected to report significant profits in the coming years.
InvestmentAcquisition
growth-negative
Here's Why InMode (INMD) Fell More Than Broader Market
InModes stock closed at $23.55, reflecting a -1.88% shift from the previous trading days closing. The stock underperformed the S&P 500, which registered a loss of 0.32% for the day. InModes stock has climbed by 14.5% in the past month, outperforming the Medical sectors gain of 2.33% and the S&P 500s gain of 4.59%. The company is expected to report EPS of $0.68, down 12.82% from the prior-year quarter, and a revenue of $126.2 million, reflecting a 5.52% fall from the equivalent quarter last year. InMode is currently sporting a Zacks Rank of #4 (Sell).
Public Trading
Growth-Negative
InMode (INMD) Sees a More Significant Dip Than Broader Market: Some Facts to Know
InModes latest trading session ended at $24.03, a 0.99% decrease from its previous close. This underperformed the S&P 500s 0.06% loss on the day. Over the past month, InModes shares have appreciated by 9.13%, outperforming the Medical sectors gain of 1.65% and the S&P 500s gain of 3.36%. The company is set to announce its earnings on February 13, 2024, with an expected EPS of $0.68, a 12.82% fall compared to the same quarter of the previous year. The companys revenue is projected to be $126.2 million, a 5.52% fall from the equivalent quarter last year.
Public Trading
growth-positive
InMode Stock (NASDAQ:INMD): 2 Catalysts That Can Send Shares Skyrocketing
Medical devices company InMode has seen a significant drop in its stock value over the past two years, falling 76% from its highs. However, the company is now seen as poised for growth, with potential catalysts including the possibility of an activist investor pushing for share buybacks or the company making an acquisition. Despite lowering its guidance in recent months and facing uncertainty due to the Israel-Hamas war, InMode is still seen as a strong investment due to its low valuation and strong balance sheet, which includes a $675.85 million cash position and no debt. The companys primary clientele includes healthcare professionals such as plastic surgeons, dermatologists, and gynecologists.
InvestmentAcquisition
growth-negative
InMode (INMD) Stock Declines While Market Improves: Some Information for Investors
InModes stock closed at $22.72, marking a 1.17% decrease from the previous session. This lagged behind the S&P 500s 0.08% gain. In the past month, InModes shares have lost 0.04%. The companys upcoming earnings report is expected to show a year-over-year decline of 12.82%. The company is currently trading with a Forward P/E ratio of 8.95, which is lower than its industrys average of 20.85. InMode currently holds a Zacks Rank of #5 (Strong Sell).
Public Trading
Growth-Negative
InMode (INMD) Stock Falls Amid Market Uptick: What Investors Need to Know
InMode (INMD) closed at $22.99 in the latest trading session, marking a -0.35% move from the previous day. This was less than the S&P 500s daily gain of 0.29%. Over the last month, InModes shares have increased by 1.54%, not keeping up with the Medical sectors gain of 2.29% and the S&P 500s gain of 2.08%. The companys earnings report is set to be unveiled on February 13, 2024, with earnings per share (EPS) projected to be $0.68, a 12.82% decrease from the same quarter last year. Revenue is forecasted to be $126.2 million, indicating a 5.52% decline compared to the corresponding quarter of the prior year.
Public Trading
growth-negative
InMode (INMD) Rises As Market Takes a Dip: Key Facts
InModes stock closed at $21.88, marking a 1.44% increase from the previous day. However, the companys shares have seen a loss of 5.97% over the past month. Analysts and investors are closely watching InModes performance ahead of its upcoming earnings report, set to be released on February 13, 2024. The company is expected to post an EPS of $0.62, a 20.51% decline compared to the same quarter last year. The Zacks Consensus Estimate for revenue is projecting net sales of $125.5 million, down 6.04% from the year-ago period. InMode is currently a Zacks Rank #5 (Strong Sell).
Public Trading
growth-positive
InMode to Report Fourth Quarter & Full Year 2023 Financial Results and Hold Conference Call on Feb. 13, 2024, Expects Q4 Revenue Between $126.0M-$126.5M
InMode Ltd., a global provider of innovative medical technologies, is set to release its financial results for Q4 and the full year of 2023 on February 13, 2024. Preliminary results suggest Q4 revenue to be between $126.0 million and $126.5 million, and full-year revenue to be between $491.3 million and $491.8 million. Non-GAAP earnings per diluted share for Q4 and the full year are expected to be in the range of $0.68 to $0.69 and $2.54 to $2.55, respectively. The company also projects its full-year 2024 revenue to be between $495 million and $505 million.
Customers
growth-positive
Is InMode Ltd. (NASDAQ:INMD) Trading At A 40% Discount?
InMode Ltd. is estimated to be 40% undervalued based on its current share price of $20.78, with a fair value estimate of $34.50. This valuation was determined using the Discounted Cash Flow (DCF) model, which takes into account expected future cash flows and discounts them to todays value. The companys total value, or equity value, is $2.9 billion. Despite the company appearing undervalued, the DCF model does not consider the possible cyclicality of an industry, or a companys future capital requirements, so it does not give a full picture of a companys potential performance.
Investment
growth-negative
InMode (INMD) Outperforms Broader Market: What You Need to Know
InModes stock price reached $21.37, a 1.96% increase compared to the previous day, outpacing the S&P 500s daily gain of 1.41%. However, the companys stock has fallen by 3.59% in the past month, lagging behind the Medical sectors gain of 6.57% and the S&P 500s gain of 2.9%. InMode is projected to report earnings of $0.62 per share in its upcoming release, a year-over-year decline of 20.51%. The company is currently trading at a Forward P/E ratio of 7.94, a discount compared to the average Forward P/E of 21.31 of its industry.
Public Trading
growth-negative
3 Boneheaded Investing Mistakes I Pledge Not to Make (Again) in 2024 and Beyond
The author reflects on his three worst investment mistakes, which include doubling down on a losing position with InMode, getting caught up in the speculative frenzy of cryptocurrency with Shiba Inu, and selling a winner too soon with AbbVie. He advises against buying more shares of a stock as it continues to fall, warns against the fear of missing out on big gains during a speculative frenzy, and encourages letting winners run for as long as they can.
Investment
growth-negative
InMode (INMD) Advances While Market Declines: Some Information for Investors
InModes stock reached $21.01 in the latest market close, a slight increase of 0.05% compared to the previous day. However, the companys stock has dropped by 1.22% in the past month. Investors are eagerly waiting for InModes upcoming earnings disclosure, where the company is expected to report an EPS of $0.62, down 20.51% from the prior-year quarter. Revenue is also expected to drop by 6.04% compared to the year-ago quarter. InMode currently holds a Zacks Rank of #4 (Sell) and has a Forward P/E ratio of 7.95, which is a discount compared to the industry average.
Public Trading
growth-negative
Is InMode (INMD) a Buy as Wall Street Analysts Look Optimistic?
InMode (INMD) has an average brokerage recommendation (ABR) of 2.00, indicating a Buy rating. However, the article suggests that investors should not solely rely on this information as brokerage recommendations often have little success in guiding investors to choose stocks with the most potential for price appreciation. This is due to the vested interest of brokerage firms in a stock they cover, which often results in a strong positive bias. The article also mentions that the Zacks Consensus Estimate for InModes current year earnings has declined 4% over the past month to $2.48, resulting in a Zacks Rank #4 (Sell) for InMode.
Investment
growth-negative
InMode (INMD) Exceeds Market Returns: Some Facts to Consider
InModes stock ended at $22.54 in the latest trading session, marking a 0.18% increase from its previous close. This performance was ahead of the S&P 500s daily gain of 0.04%. However, the companys shares had lost 5.46% over the past month. The investment community is closely watching InModes upcoming earnings performance. The company is expected to report an EPS of $0.62, a 20.51% decrease from the same quarter last year. Revenue is anticipated to be $125.5 million, a 6.04% decrease from the same quarter last year. For the entire fiscal year, earnings are predicted to be $2.48 per share and revenue $490.8 million.
Public Trading
growth-positive
InMode Ltd. (NASDAQ:INMD) is a favorite amongst institutional investors who own 73%
InMode Ltd. is largely owned by institutional investors, who hold 73% of the company. The largest shareholder is BlackRock, Inc., with a 6.6% stake. The second and third largest shareholders hold 5.8% and 4.2% respectively. InModes CEO, Moshe Mizrahy, owns 3.5% of the shares. The top 25 shareholders collectively own 50% of the company. The general public owns 13% of the company. The high level of institutional ownership indicates a high level of confidence in the companys future, but also presents a risk if these institutions decide to sell their shares.
Investment
growth-negative
InMode Ltd. (INMD) is Attracting Investor Attention: Here is What You Should Know
InMode, a maker of cosmetic surgery devices, has seen its shares return +6.4% over the past month. However, the company is expected to post earnings of $0.62 per share for the current quarter, representing a year-over-year change of -20.5%. The consensus sales estimate of $125.5 million for the current quarter points to a year-over-year change of -6%. The companys Zacks Rank is #4 (Sell), suggesting it may underperform the broader market in the near term.
Public Trading
growth-negative
Do Options Traders Know Something About InMode (INMD) Stock We Don't?
Investors in InMode Ltd. are advised to pay attention to the stock due to recent movements in the options market. The Jan 19, 2024 $105.00 Call had some of the highest implied volatility of all equity options. Implied volatility indicates expected market movement and high levels suggest investors are expecting a significant move in the stock. InMode is currently a Zacks Rank #4 (Sell) in the Medical - Products industry. Over the last 30 days, no analysts have increased the earnings estimates for the current quarter, while one has revised the estimates downwards.
Investment
growth-positive
12 Best Healthcare Stocks For the Long-Term
The article discusses the potential of the healthcare industry, highlighting the role of AI in drug discovery and patient data analysis. It mentions several healthcare companies such as Pfizer, Eli Lilly, and Novo Nordisk, and their investments in research and development. The article also lists top healthcare stocks for long-term investment, including InMode Ltd., Centene Corporation, and The Cigna Group. The global healthcare industry is expected to be worth $7.3 trillion by the end of the year, with a CAGR of 21.92%. The healthcare services market alone was worth $10.3 trillion in 2021 and is expected to post a CAGR of 8.2% between 2023 and 2030.
InvestmentCustomers
Growth-Negative
InMode Revises Full-Year 2023 Guidance
InMode Ltd., a leading global provider of innovative medical technologies, has revised its full-year 2023 guidance due to stronger-than-expected headwinds from the current macroeconomic environment. This has resulted in a slowdown in platform sales, mainly in North America. The company now expects revenue for the full year 2023 to be in the range of $485 million to $495 million, down from the prior estimated range of $500 million to $510 million. Non-GAAP income from operations is also expected to be lower than previously estimated.
Customers
Growth-Negative
NanoString Technologies (NSTG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
NanoString Technologies is expected to report a year-over-year increase in earnings on higher revenues for the quarter ended September 2023. However, the companys stock price might be influenced by how the actual results compare to these estimates. The earnings report, expected to be released on November 6, 2023, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower. The company is expected to post a quarterly loss of $0.53 per share in its upcoming report, which represents a year-over-year change of +32.9%. Revenues are expected to be $45.92 million, up 55.5% from the year-ago quarter.
CustomersPublic Trading
growth-negative
InMode (INMD) Registers a Bigger Fall Than the Market: Important Facts to Note
InModes stock price has decreased by 37.8% over the last month, underperforming the Medical sectors loss of 5.4% and the S&P 500s loss of 2.65%. The company is expected to release its earnings report on November 2, 2023, with an anticipated EPS of $0.60, a 9.09% fall compared to the same quarter of the previous year. However, revenue is projected to rise by 1.46% to $123 million. InMode currently holds a Zacks Rank of #5 (Strong Sell).
Investment
growth-negative
Analysts Estimate InMode (INMD) to Report a Decline in Earnings: What to Look Out for
InMode (INMD) is expected to report a year-over-year decline in earnings despite higher revenues for the quarter ended September 2023. The earnings report, due on November 2, 2023, could influence the companys stock price. The company is expected to post quarterly earnings of $0.60 per share, a year-over-year change of -9.1%, with revenues expected to be $123 million, up 1.5% from the year-ago quarter. However, the consensus EPS estimate for the quarter has been revised 11.27% lower over the last 30 days. The company currently carries a Zacks Rank of #5.
Investment
growth-positive
Capital Allocation Trends At InMode (NASDAQ:INMD) Aren't Ideal
InMode, a medical equipment company, has been identified as a potential multi-bagger due to its high Return On Capital Employed (ROCE). Despite a decrease from 48% to 31% over the past five years, the companys ROCE remains significantly above the industry average of 9.4%. This decrease is attributed to the companys decision to invest more in growth, which has resulted in increased capital employed and revenue. InMode has also reduced its current liabilities to 8.3% of total assets, reducing risk and increasing the companys efficiency at generating ROCE.
Investment
growth-negative
Here is What to Know Beyond Why InMode Ltd. (INMD) is a Trending Stock
InMode, a maker of cosmetic surgery devices, has seen its shares fall by 37.1% over the past month, compared to a 2.3% change in the Zacks S&P 500 composite. The company is expected to post earnings of $0.60 per share for the current quarter, a decrease of 9.1% from the same period last year. The consensus earnings estimate for the current fiscal year is $2.55, a year-on-year change of +5.4%. However, this estimate has fallen by 6.9% over the past 30 days. InModes stock is currently rated as a Strong Sell by Zacks due to the recent change in consensus estimate and other factors.
Public Trading
Growth-Positive
InMode (INMD) to Post Q3 Earnings: What's in the Cards?
InMode Ltd. is set to report its third-quarter 2023 results on November 2. The company is expected to have registered strong growth due to robust disposable sales, with sales from its platforms reaching over 1,600 units and the number of disposables sold totaling over 270,000. InMode has also established two new subsidiaries in Japan and Germany, which is expected to have benefited its third-quarter revenues. The company is also expected to report strong consumable and service revenues due to increased brand recognition and demand. However, a challenging macroeconomic environment and currency headwinds may have impacted the companys performance.
CustomersExpand
InMode (INMD) Stock Moves -0.81%: What You Should Know
2 Healthcare Stocks Near Their 52-Week Lows That Could Double in Value
InMode (INMD) Registers a Bigger Fall Than the Market: Important Facts to Note
Growth-Positive
InMode Files Patent Infringement Complaint Against BTL Industries, Inc. (d/b/a BTL Aesthetics)
InMode Ltd., a global provider of innovative medical technologies, has filed a patent infringement complaint against BTL Industries. The complaint alleges that BTL Industries UltraFemme 360 and EmFemme 360 products infringe on InModes U.S. Patent No. 8,961,511. InModes Chief Technology Officer, Dr. Michael Kreindel, stated that the company has committed significant resources to the development of minimally invasive RF technologies and has acquired cutting-edge technology to complement its own developments. He added that the company would take swift action to protect its intellectual property.
Acquisition
growth-negative
InMode Expects Third Quarter 2023 Revenue Between $122.8M-$123.0M, Lowering Full-Year 2023 Revenue Guidance to $500M-$510M vs. Original Estimates of $530M-$540M
InMode Ltd., a global provider of innovative medical technologies, is set to release its financial results for Q3 2023. Preliminary results indicate a potential impact on InModes platform sales due to economic slowdown, slower purchase decisions, and constraints in medical equipment financing. Revenue for Q3 2023 is expected to be between $122.8 million and $123.0 million, with full-year revenue estimates revised down to $500 million - $510 million from the previous $530 million - $540 million. The company will host a conference call to discuss the results on November 2, 2023.
Customers
Q4 Stock Predictions: 3 Stocks Ready to Roar Into 2024
Unveiling InMode Ltd (INMD)'s Market Leadership: A Comprehensive Analysis of Financial Growth ...
growth-positive
InMode Affirms Safety of Management, Employees and Production Sites
InMode Ltd., a global provider of innovative medical technologies, has addressed the status of the companys activity in Israel. The companys CEO, Moshe Mizrahy, stated that InMode is committed to supporting all customers, distributors, employees, and salespeople worldwide. He also mentioned that the company does not anticipate any interruption to production, as their inventory levels globally and in Israel are sufficient for the next three quarters. The company also ensures continuous customer support and exceptional service. The revenue generated from Israel is less than 1%.
CustomersManagement Changes
Growth-Negative
InMode (INMD) Stock Sinks As Market Gains: What You Should Know
InModes stock closed at $30.13, down 1.08% from the previous trading session. This lagged behind the S&P 500s 0.01% gain on the day. Over the past month, shares of the cosmetic surgery device maker have lost 22.87%. InMode is projected to report earnings of $0.69 per share in its next earnings release, representing year-over-year growth of 4.55%. The Zacks Consensus Estimate for revenue is projecting net sales of $140.1 million, up 15.57% from the year-ago period. InModes full-year Zacks Consensus Estimates are calling for earnings of $2.72 per share and revenue of $541.1 million.
growth-negative
Is Trending Stock InMode Ltd. (INMD) a Buy Now?
InMode, a maker of cosmetic surgery devices, has seen its shares return -22.9% over the past month. Despite this, the company is expected to post earnings of $0.69 per share for the current quarter, a year-over-year change of +4.6%. The consensus sales estimate for the current quarter is $140.1 million, indicating a year-over-year change of +15.6%. InModes valuation is considered to be trading at a discount to its peers. The companys Zacks Rank is #3 (Hold), suggesting it may perform in line with the broader market in the near term.
Public Trading
Growth-Negative
InMode (INMD) Stock Moves -0.52%: What You Should Know
InModes stock closed at $32.24, a 0.52% decrease from the previous trading session. This is narrower than the S&P 500s daily loss of 1.47%. Over the past month, InModes shares have lost 14.5%. As the company approaches its next earnings release, it is projected to report earnings of $0.69 per share, a year-over-year growth of 4.55%, and quarterly revenue of $140.1 million, up 15.57% from the year-ago period. For the full year, earnings are projected at $2.72 per share and revenue at $541.1 million, representing changes of +12.4% and +19.11%, respectively, from the prior year.
Public Trading
Growth-Positive
Betting Big: 3 Forgotten Stocks Primed for a Breakout
The article discusses the potential growth of certain forgotten stocks that are not currently making headlines but are predicted to soar in the future. These include Nvidia, whose stock price has risen by 140% due to the traction gained by artificial intelligence. International Business Machines (IBM) is also highlighted for its successful cloud business and AI software offering, WatsonX. Gevo, a company developing sustainable aviation fuel, and InMode, a company marketing radio-frequency powered surgical devices, are also mentioned as promising investments. The article suggests that these companies are being quietly accumulated by big money investors while their stock prices are still low.
Investment
Is Most-Watched Stock InMode Ltd. (INMD) Worth Betting on Now?
growth-negative
InMode (INMD) Dips More Than Broader Markets: What You Should Know
InMode (INMD) closed at $33.07 in the latest trading session, marking a -1.96% move from the previous day. This lagged behind the S&P 500s 0.94% loss on the day. Over the past month, shares of the maker of cosmetic surgery devices had lost 10.77%, lagging the Medical sectors loss of 0.55% and the S&P 500s gain of 1.85%. Analysts expect InMode to post earnings of $0.69 per share in its next earnings release, marking year-over-year growth of 4.55%. The companys full-year Zacks Consensus Estimates are calling for earnings of $2.72 per share and revenue of $541.1 million.
Public Trading
growth-positive
InMode (INMD) Outpaces Stock Market Gains: What You Should Know
InMode (INMD) closed at $34.91 in the latest trading session, marking a 1.28% increase from the previous day. This outpaced the S&P 500s daily gain of 0.84%. Despite losing 9.5% in the past month, investors are hopeful as InMode approaches its next earnings release. The company is expected to report an EPS of $0.69, up 4.55% from the prior-year quarter, and net sales of $140.1 million, up 15.57% from the year-ago period. InMode currently has a Zacks Rank of #3 (Hold).
Public Trading
Growth-Negative
InMode (INMD) Stock Sinks As Market Gains: What You Should Know
InModes shares closed at $37.91 in the latest trading session, marking a 0.73% decrease from the prior day. This lagged behind the S&P 500s 0.14% gain. Over the past month, shares of the cosmetic surgery device maker have lost 6.14%. As InMode approaches its next earnings report, it is expected to report an EPS of $0.69, up 4.55% from the prior-year quarter. Revenue is expected to be $140.1 million, up 15.57% from the prior-year quarter. For the full year, analysts are expecting earnings of $2.72 per share and revenue of $541.1 million.
growth-negative
InMode Ltd. (INMD) is Attracting Investor Attention: Here is What You Should Know
InMode, a maker of cosmetic surgery devices, has seen its shares return -9.9% over the past month, compared to the Zacks S&P 500 composites +0.6% change. Despite this, the companys Zacks Rank #2 (Buy) suggests it may outperform the broader market in the near term. For the current quarter, InMode is expected to post earnings of $0.69 per share, a change of +4.6% from the year-ago quarter. The consensus sales estimate for the current quarter of $140.1 million indicates a year-over-year change of +15.6%. InModes valuation is graded C, indicating it is trading at par with its peers.
Public Trading
Growth-Positive
InMode to Present at Upcoming Investor Conferences and Events
InMode Ltd., a global provider of innovative medical technologies, has announced its participation in several investor conferences and events in September. These include the Baird Healthcare Conference, Piper Sandler Aesthetics Day, and Cantor Global Healthcare Conference. The company will be represented by its Chief Financial Officer, Yair Malca, and other key personnel. The events will feature in-person fireside chats, one-on-one meetings, and a live webcast of the presentations.
Partners
Growth-Positive
Is HealthEquity (HQY) Outperforming Other Medical Stocks This Year?
HealthEquity (HQY) is outperforming its peers in the Medical sector, according to Zacks Investment Research. The companys full-year earnings consensus estimate has moved 17.4% higher within the past quarter, indicating improved analyst sentiment and a stronger earnings outlook. So far this year, HealthEquity has gained about 7.8%, while Medical stocks have lost an average of 3.3%. Another Medical stock that has outperformed the sector is InMode (INMD), which is up 10.6% year-to-date.
Investment
growth-positive
12 Cheapest and Best Countries for Plastic Surgery
The article discusses the global cosmetic surgery market and highlights Evolus, Inc as a performance beauty company operating in the cash-pay aesthetic market. Evolus reported impressive Q2 2023 results and increased its full-year 2023 net revenue guidance. The article also mentions other trends and companies in the plastic surgery industry, including AirSculpt Technologies and InMode Ltd. It then provides a list of the 12 cheapest and best countries for plastic surgery, including the Dominican Republic, Poland, Colombia, Spain, Greece, Lithuania, and Germany.
Customers
growth-positive
InMode (INMD) Outpaces Stock Market Gains: What You Should Know
InModes stock closed at $39.49, showing a +1.02% move. The companys stock performance has lagged behind the Medical sector and the S&P 500. Analysts expect InMode to post earnings of $0.69 per share, with a year-over-year growth of 4.55%. The Zacks Consensus Estimate for revenue is projecting net sales of $140.1 million, up 15.57% from the previous year. For the full year, earnings are projected to be $2.72 per share and revenue to be $541.1 million, representing changes of +12.4% and +19.11%, respectively. InMode is currently trading at a Forward P/E ratio of 14.73, which is a discount compared to the industry average. The company has a Zacks Rank of #2 (Buy).
Public Trading
growth-positive
10 Best Cosmetic Surgery and Aesthetics Stocks to Buy
The cosmetic surgery and aesthetics sector is witnessing a shift in trends, with a growing preference for a more natural appearance. Liposuction remains consistently popular, with a recent influx of patients seeking distinct and tailored liposuction techniques. The market is predicted to grow at a CAGR of around 6.34% between 2021 and 2028. The cost of procedures is decreasing due to the increased number of available cosmetic surgeons and alternative treatments. The global cosmetic surgery market is anticipated to reach $43.9 billion by 2025. The best stocks to buy in this sector include Zimmer Biomet Holdings, InMode Ltd., Cutera, Inc., Aesthetic Medical International Holdings Group Limited, Sientra, Inc., Milestone Scientific Inc., So-Young International Inc., and AirSculpt Technologies, Inc.
InvestmentCustomers
growth-negative
Want to Get Rich? 3 Game-Changing Sleeper Stocks to Buy Right Now
The article discusses sleeper stocks that present investment opportunities. It highlights three sleeper stocks, including Perion, Deere & Company, and Inmode, that have the potential for high returns. Perion is an ad-tech company with double-digit revenue and earnings growth and a low valuation. Deere & Company has a reasonable valuation and recently delivered strong earnings growth. Inmode is an Israeli-based company that produces medical devices and has experienced record-breaking revenue growth. The article emphasizes that these sleeper stocks have more reasonable valuations and better financials compared to stocks that receive more attention. The article was published on an unknown date.
Valuation
growth-positive
10 Stocks That Will Change the Future
The article discusses the impact of technological advancements, particularly artificial intelligence (AI), on various companies and their potential for future growth. NVIDIA Corporation is highlighted for its work in the AI field, particularly its new AI processor, the Grace Hopper Superchip. Microsoft Corporations investment in OpenAI, the company behind ChatGPT, is also mentioned. Other companies discussed include Medtronic plc, which is integrating AI into its products, and Alphabet Inc., which acquired AI company DeepMind in 2014. The article also lists several stocks that are expected to change the future, including SenseTime Group Inc., ABB Ltd, Mobileye NV, InMode Ltd., and Rockwell Automation Inc.
InvestmentAcquisition
growth-negative
InMode Ltd. (INMD) Is a Trending Stock: Facts to Know Before Betting on It
InMode, a maker of cosmetic surgery devices, has experienced a negative stock performance over the past month. The article discusses the importance of earnings estimates and revenue growth in determining a companys stock value. InMode is expected to post positive earnings for the current quarter, but the consensus estimate has decreased over the last 30 days. The companys potential revenue growth is also highlighted. InMode has a strong track record of beating earnings estimates and has a Zacks Rank #2 (Buy). The article also mentions the companys valuation, indicating that it is trading at par with its peers. Overall, the article suggests that while the recent stock performance may be negative, InMode has the potential to outperform the broader market in the near term.
Customers
growth-positive
The 7 Most Undervalued Forever Stocks to Buy Now: August 2023
The article discusses seven undervalued forever stocks to buy, including Costco, Microsoft, Visa, Broadcom, Inmode, Cisco, and Procter & Gamble. It highlights the loyalty of Costco customers and the companys resilience during recessions. Microsofts dominance in various sectors and its consistent dividend growth are mentioned. Visa faces short-term headwinds but has a reliable long-term business model. Broadcom is well-positioned to profit from the rising demand for AI chips. Inmode is a hidden gem with excellent revenue and earnings growth. Ciscos business model is showing signs of a rebound, and Procter & Gamble is a dividend aristocrat with a diversified product portfolio. The article emphasizes the importance of focusing on elevating income and investing in undervalued stocks for long-term success.
Customers
growth-positive
Has HealthEquity (HQY) Outpaced Other Medical Stocks This Year?
HealthEquitys stock performance is outperforming its peers in the Medical sector, according to Zacks Investment Research. The company has gained about 9.9% year-to-date, while the Medical sector has returned an average of -2.8%. HealthEquity is also ranked #6 within the Zacks Sector Rank for the Medical group. The Zacks Rank, which considers earnings estimates and estimate revisions, gives HealthEquity a rank of #2 (Buy). In comparison, another Medical stock, InMode, has returned 6.7% year-to-date and has a Zacks Rank of #2. HealthEquity belongs to the Medical Services industry, which has lost an average of 7.6% so far this year, while InMode belongs to the Medical - Products industry, which has moved -1.6%.
CustomersPartners
growth-positive
Got $5,000? Here's 3 Reasons to Buy InMode Stock Right Now
InMode, a company that specializes in innovative, less-invasive devices for medical-aesthetics treatments, is being highlighted as a good investment opportunity. The company is poised to take market share from traditional beauty interventions like plastic surgery and laser treatments. InModes second-quarter sales have increased by 20%, reaching over $136 million, thanks to its global sales force and distribution operations.
Investment
growth-positive
This 1 Number Shows Why InMode Stock Is a Buy
InMode, a company that manufactures workstations for plastic surgeons and other medical aesthetics practitioners, is being touted as a good stock buy. The companys products, which include devices for reshaping figures, toning muscles, eliminating fat deposits, and removing hairs, require consumables like cannulas and treatment applicators that are intended for one-time use. The more customers use InModes devices, the more consumables they need, creating a continuous demand for the companys products.
Customers
growth-positive
Here's Why We Think InMode (NASDAQ:INMD) Might Deserve Your Attention Today
InMode, a profitable tech-stock company, has seen a significant growth in its earnings per share (EPS) by 43% per year over the last three years. Despite a dampening of EBIT margins, the companys revenue growth has been positive. Insiders at InMode own shares worth US$486m, accounting for 14% of the business, indicating a close alignment of interests with shareholders. The companys fast EPS growth and large insider investment make it a potential opportunity for investors.
Investment
growth-positive
InMode to Present at Upcoming Investor Conferences and Events
InMode Ltd., a global provider of innovative medical technologies, has announced its participation in several investor conferences and events in August. The companys representatives, including the CFO and CMO, will present at Canaccord Genuitys 43rd Annual Growth Conference, Needham Virtual MedTech & Diagnostics 1x1 Conference, and UBS Med Device Conference. The presentations will be in the format of in-person fireside chats and virtual one-on-one meetings. Live webcasts of the presentations will also be available.
Investment
Growth-Positive
Is It Too Late to Buy InMode Stock?
The article discusses the performance of InModes stock, which has seen a 64% increase over the past 12 months. InMode is a popular provider in the aesthetics industry. The article does not provide further details.
growth-positive
Here's Why I'm Buying (More) InMode Stock in August
The article discusses the authors decision to increase their investment in InMode, a medical aesthetic device company, by 10%. InModes devices are used by plastic surgeons and other practitioners for procedures such as fat liquefaction, skin tightening, muscle toning, and hair removal. The company has seen a significant increase in net income over the past three years, with a rise of 115%, reaching $161 million in 2022.
Investment
growth-positive
InMode Ltd. (NASDAQ:INMD) Q2 2023 Earnings Call Transcript
InMode Ltd. reported its Q2 2023 earnings, revealing a record revenue of $136.1 million, a 20% increase compared to Q2 2022. The company sold over 1,600 units of its platforms and over 270,000 disposables, the highest in its history. As part of its global expansion, InMode established two new subsidiaries in Japan and Germany. The company also plans to invest heavily in product development and launch new technologies and platforms in the next 12 months. It also announced that it has become part of the Russell 2000 Index.
CustomersExpand
growth-positive
InMode (INMD) Q2 Earnings and Revenues Beat Estimates
InMode has reported its quarterly earnings, surpassing the Zacks Consensus Estimate with earnings of $0.72 per share, compared to the expected $0.70. This is an increase from the previous years earnings of $0.59 per share. The company, which manufactures cosmetic surgery devices, also reported revenues of $136.08 million for the quarter ending June 2023, a growth from the previous years $113.55 million. InModes shares have increased by 26.1% since the start of the year, outperforming the S&P 500s gain of 18.9%. The companys future performance is expected to be influenced by its earnings outlook and industry trends.
InvestmentPublic Trading
growth-positive
InMode Reports Second Quarter 2023 Financial Results; Record Quarterly Revenue of $136.1M Represents 20% Year-Over-Year Growth
InMode Ltd., a global provider of innovative medical technologies, has announced its consolidated financial results for Q2 2023. The company reported record quarterly revenue of $136.1 million, a 20% increase compared to Q2 2022. InModes proprietary surgical technology platforms represented 81% of quarterly revenues. The company also reported a record GAAP net income of $55.7 million, compared to $44.0 million in Q2 2022. The companys total cash position as of June 30, 2023, was $629.4 million.
Customers
Neutral
InMode (INMD) Q2 2023 Earnings Call Transcript
InMode (INMD) held its Q2 2023 earnings call on July 27, 2023. The call was attended by Moshe Mizrahy, chairman and CEO; Dr. Michael Kreindel, co-founder and chief technology officer; Yair Malca, chief financial officer; Shakil Lakhani, president in North America; Dr. Spero Theodorou, chief medical officer; and Rafael Lickerman, VP of finance.
Management Changes
growth-positive
Are Medical Stocks Lagging InMode (INMD) This Year?
InMode (INMD), a company in the medical group, is outperforming its peers in terms of stock performance. The company is currently sporting a Zacks Rank of #2 (Buy) and has returned about 22.6% since the start of the calendar year, compared to an average return of -1.7% for other medical companies. The Zacks Consensus Estimate for INMDs full-year earnings has moved 2.9% higher over the past 90 days, indicating an improving earnings outlook. Another medical stock, Akebia Therapeutics (AKBA), has also outperformed the sector with a return of 154.8% since the beginning of the year.
Investment
Growth-Positive
InMode (INMD) to Post Q2 Earnings: What's in the Cards?
InMode Ltd. is set to report its Q2 2023 results on July 27. The companys preliminary results suggest revenues between $135.7 million and $135.9 million, with adjusted earnings per share in the range of 70-71 cents. The companys strong performance is attributed to its patented technologies and the successful entry of its Envision platforms in Canada. However, the companys performance may have been affected by a challenging macroeconomic environment and currency headwinds. The Zacks Consensus Estimate for InModes Q2 2023 revenues is $135.8 million, a 19.6% projected improvement year over year.
Customers
growth-positive
InMode Expands Women's Health and Wellness Market Footprint through Acquisition of Viveve Patents
InMode Ltd., a global provider of innovative medical technologies, has announced the acquisition of all the intellectual property assets of Viveve Medical Inc., a company focused on womens wellness and the treatment of female stress urinary incontinence. The acquisition, along with an exclusive licensing agreement with the University of California, strengthens InModes position as a global market leader in womens wellness product development.
Acquisition
Growth-Positive
InMode (INMD) Stock Sinks As Market Gains: What You Should Know
InMode (INMD) closed at $45.21 in the latest trading session, marking a slight decrease from the prior day. However, the companys shares had gained 23.87% in the past month. InMode is expected to report its next earnings release on July 27, 2023, with projected earnings of $0.67 per share, representing a year-over-year growth of 13.56%. The Zacks Consensus Estimate for revenue is projecting net sales of $135.8 million, up 19.59% from the year-ago period. For the full year, earnings of $2.71 per share and revenue of $540 million are projected, representing changes of +11.98% and +18.87%, respectively, from the prior year.
growth-positive
Investors Heavily Search InMode Ltd. (INMD): Here is What You Need to Know
InMode, a maker of cosmetic surgery devices, has seen its shares return +22.1% over the past month, outperforming the Zacks S&P 500 composites +3.4% change. The company is expected to post earnings of $0.67 per share for the current quarter, a year-over-year change of +13.6%. The consensus sales estimate of $135.8 million for the current quarter points to a year-over-year change of +19.6%. InModes Zacks Rank is #3 (Hold), indicating that it may perform in line with the broader market in the near term.
Investment
Growth-Positive
InMode (INMD) Outpaces Stock Market Gains: What You Should Know
InMode (INMD) closed at $46.04 in the latest trading session, marking a 0.55% increase from the previous day, outpacing the S&P 500s daily gain of 0.24%. Over the past month, shares of the cosmetic surgery device maker have gained 22.07%. As the company approaches its next earnings report date on July 27, 2023, it is expected to report an EPS of $0.67, up 13.56% from the prior-year quarter. Revenue is expected to be $135.8 million, up 19.59% from the prior-year quarter. For the full year, earnings of $2.71 per share and revenue of $540 million are projected.
Public Trading
growth-positive
Institutional investors control 62% of InMode Ltd. (NASDAQ:INMD) and were rewarded last week after stock increased 13%
InMode Ltd. is significantly influenced by institutional investors, who hold around 62% of the companys shares. The top 25 shareholders own 42% of the company, and insider ownership is at 14%. The largest shareholder is Robert Mulholland, owning 5.8% of the company. The second and third largest shareholders are Acadian Asset Management LLC and Michael Kreindel, each holding 4.2% of the shares. The companys CEO, Moshe Mizrahy, directly holds 3.5% of the total shares. The general public holds a 25% stake in InMode.
Investment
growth-positive
InMode (INMD) Stock Sinks As Market Gains: What You Should Know
InMode (INMD) closed at $45.19 in the latest trading session, marking a -0.07% move from the previous day. This change lagged the S&P 500s daily gain of 0.85%. However, shares of the maker of cosmetic surgery devices had gained 24.16% in the past month. Investors are looking forward to InModes next earnings release, where analysts expect the company to post earnings of $0.67 per share, marking a year-over-year growth of 13.56%. InMode currently has a Zacks Rank of #3 (Hold).
Public Trading
Growth-Positive
Why InMode Stock Flew to a New 52-Week High Today
Shares of cosmetic medical device company InMode reached new 52-week highs after the company released its preliminary financial results for the second quarter of 2023 and raised its guidance for the year. The stock was up almost 11%.
Customers
growth-positive
3 Hypergrowth Stocks to Catapult You into the Millionaires’ Club
The article discusses three hypergrowth stocks - InMode, Fortinet, and ServiceNow - that have the potential to provide high returns to investors. InMode, an Israeli-based company that provides innovative medical technology, has high-profit margins and high revenue growth. Fortinet, a cybersecurity company, has double-digit revenue growth and healthy profit margins. ServiceNow, a cloud computing company, recently exceeded expectations and raised guidance for 2023. The company reported 24% year-over-year revenue growth and doubled its net income.
Investment
InMode, A Top 1% Profit Machine, Breaks Out On Solid Preannouncement — But There's A Caveat
growth-positive
biote Corp. (BTMD) Moves 5.3% Higher: Will This Strength Last?
biote Corp. saw a 5.3% increase in its shares in the last trading session, closing at $6.76. This growth is attributed to the announcement of a new Mens Health Division and anticipated better-than-expected Q2 2023 revenues. The companys earnings per share are expected to be $0.11 in its upcoming report, representing a year-over-year change of -59.3%. Revenues are expected to be $46.93 million, up 13.5% from the year-ago quarter. The stock currently carries a Zacks Rank #3 (Hold).
Expand
Growth-Positive
InMode Expects Second Quarter 2023 Revenue Between $135.7-$135.9M, Increases Full Year 2023 Guidance, Expects Revenues of $530-540M
InMode Ltd., a global provider of innovative medical technologies, is set to release its financial results for the second quarter of 2023 on July 27, 2023. Preliminary results indicate a revenue for the second quarter in the range of $135.7 million to $135.9 million and non-GAAP earnings per diluted share in the range of $0.70 to $0.71. The company also increased its revenue guidance for the full year of 2023 to be in the range of $530 million to $540 million, up from the previous guidance of $525-$530 million.
Customers
Neutral
4 Top Stocks to Buy in July and Hold Forever
The article from Motley Fool suggests that now may be the perfect time to buy certain stocks, as the long-term growth stories of these businesses are still in their early chapters. The article does not specify which stocks are being referred to.
growth-positive
3 Top-Tier Stocks Trading at Historical Discounts
The article discusses three exceptional stocks: Visa, InMode, and VeriSign, that have compelling valuations and strong business fundamentals. Visa, the worlds leader in credit card transactions, is expected to continue growing as it expands internationally. InMode, a medical technology company, has experienced significant growth in sales and is projected to continue growing. VeriSign, a trusted provider of domain name registry services, benefits from the increasing demand for domain names and online presence. The article highlights the discounted valuations of these stocks, making them attractive investment opportunities. The date of the event described in the article is not provided.
Customers
growth-positive
Is Cellectar Biosciences (CLRB) Outperforming Other Medical Stocks This Year?
Cellectar Biosciences, Inc. (CLRB) is outperforming its peers in the Medical group, according to Zacks Investment Research. The companys full-year earnings consensus estimate has increased by 19.9% within the past quarter, indicating an improving analyst sentiment and a more positive earnings outlook. So far this year, CLRB has returned 8.2%, outperforming the Medical sectors average return of -2.3%. Another Medical stock, InMode (INMD), has also outperformed the sector with a year-to-date return of 3%.
Investment
growth-positive
3 Millionaire-Maker Growth Stocks to Buy And Hold Forever
The article discusses three high-potential growth stocks that can help investors build a 7-figure portfolio. One of the stocks mentioned is ServiceNow, a leader in the cloud computing industry. ServiceNow has a large customer base and achieved 24% year-over-year revenue growth in the first quarter. The companys position in the growing cloud computing industry is seen as a positive factor for its future growth. However, the article notes that the companys valuation is high, with a P/E ratio of over 285. The article suggests that the industrys growth runway could lead to a more reasonable valuation in the future.
Customers
growth-positive
7 Healthcare Stocks to Make You the Millionaire Next Door
Revance Therapeutics has launched Daxxify, an anti-wrinkle treatment that lasts longer than Botox. The treatment has already generated revenue of $15.4 million for the company in the first quarter.
Customers
growth-positive
Is InMode (INMD) Outperforming Other Medical Stocks This Year?
InMode, a company in the medical sector, is currently outperforming its peers, according to Zacks Investment Research. The company is one of 1143 individual stocks in the medical sector, which collectively sit at #6 in the Zacks Sector Rank. The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. InMode currently has a Zacks Rank of #2 (Buy). The Zacks Consensus Estimate for InModes full-year earnings has moved 5.2% higher, indicating that analyst sentiment is stronger and the stocks earnings outlook is improving.
Investment
growth-positive
InMode Stock Performs Beautifully. Big Money Still Wary Though.
InMode, a medical technology maker, saw its stock rise by 3% on Monday, continuing to outperform the market. The companys Relative Strength (RS) Rating also rose into the 80-plus percentile with an improvement to 81, marking a significant performance benchmark. Despite this, big money investors remain wary of the stock.
growth-positive
The 3 Most Undervalued Value Stocks to Buy in June 2023
The article discusses the best undervalued value stocks for June, highlighting Dr. Reddys Laboratories as one of the top picks. Dr. Reddys Laboratories is a multinational pharmaceutical company based in India. The company has a wide range of pharmaceutical products and strong operational stats. It is considered an undervalued stock with potential for growth. Wall Street analysts rate it as a moderate buy with an average price target of $67, implying a 20% upside potential.
Investment
growth-positive
Declining Stock and Solid Fundamentals: Is The Market Wrong About InMode Ltd. (NASDAQ:INMD)?
InModes share price has fallen by 4.3% over the past three months, but the companys strong financials suggest it is still a good investment. The companys return on equity (ROE) is 28%, significantly higher than the industry average of 9.8%. This high ROE has contributed to InModes impressive net income growth of 43% over the past five years. The company does not pay dividends, instead reinvesting all profits back into the business. However, industry analysts predict that InModes earnings growth will slow down in the future.
Investment
growth-positive
The Zacks Analyst Blog Highlights InMode, Johnson & Johnson, Intuitive Surgical and GE HealthCare
The article discusses the emergence of a bullish market in the medical device sector, fueled by positive earnings reports from various companies. It highlights the rebound of non-urgent surgeries as a contributing factor to the industrys growth. The key companies mentioned in the article are InMode, Johnson & Johnson, Intuitive Surgical, and GE HealthCare, which have demonstrated strong performance and potential for future success. InMode is benefiting from market growth with its minimally-invasive radio frequency devices. Johnson & Johnsons medical devices division has seen success despite legal challenges. Intuitive Surgical has recorded impressive growth in robotic surgery, and GE HealthCares diagnostic equipment division is expected to drive its performance. The article concludes by stating that the medical device industry holds promise for investors.
CustomersPartners
growth-positive
7 Stocks Under $50 to Buy (and Never Sell)
The article discusses seven affordable stocks to invest in, including Simulations Plus. Simulations Plus is a science-focused software specialist that develops modeling and simulation software for the pharmaceutical and biotechnology industries. The company has shown growth potential and offers a relative discount, making it an attractive investment option. Analyst sentiment is strong, with a unanimous strong buy view and an average price target implying almost 37% upside potential. Simulations Plus also has a strong balance sheet and low risk of bankruptcy. The article highlights the companys potential for high return on investment.
Investment
growth-positive
Solid Earnings Fuel Potential Bull Market in Medical Devices
The medical device sector is experiencing a surge in value, with positive earnings reports from various companies indicating a growing bullish trend. The resumption of non-urgent surgeries post-pandemic has fueled an increase in the sale of medical devices, contributing to the industrys growth. Four companies - InMode, Johnson & Johnson, Intuitive Surgical, and GE HealthCare - have shown strong potential for future gains. InModes recent earnings report indicated a 43% rise in consumables and service revenues. Johnson & Johnson reported better-than-expected quarterly results, driven by the success of its medical devices division. Intuitive Surgical saw a 26% increase in the number of procedures performed worldwide, and GE HealthCares diagnostic equipment division is expected to drive its performance going forward.
Customers
growth-positive
3 Exceptional Growth Stocks You Can Buy With $200 Right Now
The article discusses the comeback of growth stocks and highlights the performance of the Vanguard Growth ETF. It mentions that growth stocks started soaring last summer but lost all their gains by the end of 2022. The article is focused on the potential of investing in growth stocks and suggests three exceptional growth stocks that can be bought with $200. The impact on the company (SHOP) is growth-positive. The key theme of the article is growth stocks. The key issues discussed are customers and partners. The date of the event described in the article is not provided. The confidence level of the answer is 8.
CustomersPartners
growth-positive
InMode (NASDAQ:INMD) Looks To Prolong Its Impressive Returns
InMode, a medical equipment company, has been identified as having a promising Return on Capital Employed (ROCE) trend. The company has consistently earned a 33% ROCE for the last five years, significantly higher than the industry average of 9.1%. The capital employed within the business has also risen by 1,692% during this period. InMode has also successfully reduced its current liabilities to 8.9% of total assets over the last five years. The companys stock has seen a 153% return over the last three years.
Investment
growth-positive
Is This the Best Healthcare Stock to Buy Right Now?
The article discusses the potential of InMode as a healthcare stock to invest in, given the current economic conditions. While many fast-growing businesses are laying off staff to cut costs due to slowing U.S. economic growth, InMode is still performing well and growing.
Layoffs
growth-positive
InMode to Present at Upcoming Investor Conferences and Events
InMode Ltd., a global provider of innovative medical technologies, has announced its participation in several investor conferences and events. The companys CEO, CFO, and CMO will present at the BNPP Exane Aesthetics Day, Barclays West Coast Bus Trip, and Jefferies Healthcare Conference. InMode develops, manufactures, and markets devices using novel radiofrequency technology to enable new surgical procedures and improve existing treatments. The company offers a comprehensive line of products across various medical fields.
Investment
Growth-Negative
2 Magnificent Growth Stocks You Can Buy With $150 Right Now
The article discusses the unpredictability of investing in growth stocks, using the example of the Nasdaq Composite, which rose 21% in 2021 but fell 33% in 2022. The article suggests that despite the volatility, investing in growth stocks is not just for Wall Street professionals.
More Likely to 5X First: Teladoc vs. InMode
Growth-Positive
1 Soaring Growth Stock That's Still an Unbeatable Bargain
The article discusses a companys minimally invasive alternative to liposuction surgery that is not getting the attention it deserves. The company is identified as a growth stock and is considered an unbeatable bargain.
Customers
growth-positive
InMode Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
InMode Ltd. has reported strong results in its latest earnings, exceeding expectations with revenues of US$106m, 2.6% ahead of forecasts. Earnings per share were also ahead of estimates at US$0.47. Analysts have updated their estimates for the companys revenues in 2023 to US$531.1m, a 12% increase on its sales over the past 12 months. Earnings per share are predicted to increase by 13% to US$2.35. The analysts have reconfirmed their price target of US$47.83, indicating that the business is performing in line with expectations.
Investment
Wall Street Analysts Think InMode (INMD) Could Surge 45.95%: Read This Before Placing a Bet
Q1 2023 Inmode Ltd Earnings Call
Growth-Negative
Why InMode Stock Is Plunging Today
InMode Ltd reported Q1 sales of $106.07 million, a 23.5% increase year-on-year, beating the consensus of $101.29 million. The company also posted an adjusted EPS of $0.52, surpassing the consensus of $0.47. However, the companys annual outlook lagged expectations, with revenues expected to be $525-$530 million compared to the consensus of $531.05 million. This news led to a plunge in the companys stock. The decrease in operating margin from 44% to 43% was primarily due to higher sales and marketing expenses.
InvestmentManagement Changes
growth-negative
InMode, A Top 1% Stock, Crumbles On Lackluster Sales, Earnings Outlook
InMode beat first-quarter expectations but experienced a decline in share value due to lackluster sales and earnings outlook.
Customers
growth-negative
Why InMode Stock Plummeted by 10% on Tuesday
The stock of medical aesthetics tech company InMode (NASDAQ: INMD) plummeted by 10% on Tuesday after the company published disappointing quarterly figures.
Public Trading
growth-positive
3 Great Foreign Companies to Invest in Right Now | The Motley Fool
MercadoLibre, InMode, and Global-e Online, despite being headquartered internationally, are trading on U.S. exchanges and have seen significant sales growth over the past year. Despite this, their share prices have dropped, presenting a potential opportunity for investors. MercadoLibres advertising business is thriving, with plans to expand the department. InMode, based in Israel, offers non-invasive alternatives to plastic surgery and plans to expand in Europe and Asia in 2023. Global-e Online, also based in Israel, offers cross-border sales to businesses of all sizes and has seen rapid adoption of its services.
InvestmentExpand
growth-positive
InMode Receives Health Canada Certification of Forma-I for Dry Eye Disease Due to Meibomian Gland Dysfunction
InMode Ltd., a global provider of innovative medical technologies, has received a Health Canada license for its Forma-I product, designed to treat symptoms of dry eye disease due to Meibomian gland dysfunction (MGD). The North American dry eye market was worth $2.4 billion in 2021, and this certification allows InMode to offer a non-drug alternative to millions of MGD and dry eye sufferers. The Forma-I uses thermal technology to deliver targeted bipolar radiofrequency energy to delicate ocular areas.
CustomersExpand
https://www.kpvi.com/news/national_news/inmode-expects-record-third-quarter-2021-revenue-of-93-5m--94m-raising-full-year/article_10b1c17f-7af3-57f6-8fce-06d93b16bcea.html
growth-positive
InMode Announces Launch of EmpowerRF Women's Wellness Platform
InMode Ltd. has launched the EmpowerRF Womens Wellness platform, a multi-functional platform that offers life-changing womens wellness therapies. The platform combines multiple complementary technologies to provide customized procedures for various conditions. InMode has invested heavily in the feminine health segment and aims to revolutionize womens wellness. The companys CEO and North American President expressed their commitment to bringing breakthrough innovations to the market. The Chief Medical Officer highlighted the impact of EmpowerRF on improving the quality of life for women globally. InMode is a leading global provider of innovative medical technologies, specializing in RF technology. They offer a comprehensive line of products for various medical fields. The launch of EmpowerRF is expected to contribute to the companys growth.
CustomersPartners
growth-positive
InMode Reports Record Third Quarter 2020 Financial Results;Quarterly Revenues of $59.7 Million Represent 49% Year over Year Growth, GAAP and *Non-GAAP Diluted Earnings per Share of $0.57 and $0.63
InMode Ltd., a global provider of innovative medical technologies, has announced its Q3 2020 financial results. The company reported record quarterly revenues of $59.7 million, a 49% increase compared to Q3 2019. The increase in revenues was primarily driven by the expansion of InModes direct sales organization in the US and the continued momentum of InModes hands-free technology. InMode also reported a GAAP net income of $23.9 million, compared to $16.2 million in Q3 2019. The company expects its revenues for the full year of 2020 to be between $192 million and $195 million.
CustomersInvestment
growth-positive
InMode Announces US Patent for Fractional RF (Morpheus8)
InMode Ltd. has been granted a patent for its Morphues8 full body fractional radiofrequency (RF) technology. The company has invested significantly in R&D to develop state-of-the-art electro-surgical bi-polar RF devices and is considered a disruptive technology leader in the industry. InMode plans to enforce its unique fractional IP and has issued cease and desist notices to companies infringing on its patent. The company aims to protect its intellectual property and grow shareholder value. InMode is a global provider of innovative medical technologies, offering a comprehensive line of products across various medical fields.
Investment
growth-positive
InMode Introduces Morpheus8 Body Multi-pulse Burst Technology
InMode Ltd. has introduced the Morpheus8 Body Multi-pulse Burst Radiofrequency Vulcanization Technology, which allows for customized full body fractional procedures. The technology deploys bipolar RF energy to multi-level treatment depths in a single cycle, reducing treatment times and minimizing skin injury. InMode is a leading global provider of innovative medical technologies and aims to enable new surgical procedures and improve existing treatments. The company has a comprehensive line of products across several categories for various medical fields. The introduction of Morpheus8 Burst solidifies InMode as the leader in the fractional market. InMode continues to innovate and redefine the medical aesthetics industry.
Expand
growth-positive
InMode Announces Share Repurchase Program of Up to 1 Million Shares
InMode Ltd. has announced a share repurchase program of up to 1 million ordinary shares. The company anticipates increased demand for its medical technologies due to new product launches and the gradual return of elective surgeries. InMode aims to capture market share, expand, and develop innovative platforms. The share repurchases will be funded with available cash. The company has been expanding its North American sales and marketing network to reaccelerate positive momentum. InMode views its shares as an attractive investment opportunity and will leverage its strong cash flow and balance sheet to support future growth. The announcement reflects the companys confidence in its ability to attract physicians and patients globally.
Investment
growth-positive
InMode Introduces the Morpheus8 Platform and the Morpheus8 Body Fractional Technology
InMode Ltd., a leading global provider of innovative medical technologies, has received FDA clearance to market the Morpheus8 Body handpiece and Morpheus8 Platform. The Morpheus8 Body is the first intelligent, programmable, full body fractional technology to deliver clinically proven RF energy up to a thermal depth of 8mm. The new Morpheus8 Body will be launched on a new Morpheus8 Platform, a state-of-the-art workstation complete with dual handpieces and four fractional tips with different microneedle configurations. The Morpheus8 Platform will be revealed to the North American market at InModes Main Event on August 14 – 16, 2020.
CustomersExpand
growth-positive
InMode Announces NMPA (formerly CFDA) Approval for Two InMode Platforms in China
InMode Ltd., a global provider of innovative medical technologies, has received clearance from the China National Medical Products Administration for two of its radiofrequency platforms. The InMode RF platform and the InMode system are designed for minimally invasive facial remodeling and body liposuction procedures, and for treating wrinkles and tightening skin, respectively. In 2019, InMode established an exclusive partnership with Beijing Inmode Medical Technology Co., Ltd, to distribute InModes products in China. The company plans to begin sales in Q3, 2020.
CustomersPartnersExpand
growth-positive
Medical Aesthetic Company InMode in Talks for Secondary Offering
Israel-based InMode Aesthetic Solutions Ltd. is planning a secondary offering valued at hundreds of millions of dollars. The company, which develops medical aesthetic devices, was listed on Nasdaq in August at a $450 million company valuation but has since reached a $1.3 billion market capitalization. The companys co-founder and CEO, Moshe Mizrahi, has been in talks with Wall Street banks to advance the matter. Around 30% of the company’s stock is held by employees, who might participate in the secondary offering. Large shareholders expected to participate are Israel HealthCare Ventures, co-founder and chief technology officer Michael Kreindel, and Mizrahi.
InvestmentPublic Trading
growth-positive
Dreams of Eternal Youth Boost InMode's Valuation
InMode Aesthetic Solutions Ltd., a medical aesthetic devices manufacturer, has doubled its market capitalization since its August IPO on Nasdaq, surpassing the $1 billion mark. The companys successful IPO and growth rate have made it one of Wall Streets top three IPOs of the past 12 months. InMode stands out compared to other recent Israeli IPOs, with a higher market capitalization than Fiverr Int. Ltd. and a better stock performance than Uber. Investors are enthusiastic about InMode due to its growth rate and net profit, which is uncommon among companies that went public in the past year. The companys strong financial results, including high gross profit margins and profitability since 2017, contribute to its investor appeal. InMode sells its medical aesthetic devices directly to doctors, allowing for higher pricing. The founders and major shareholders of InMode have benefited from the companys stock performance. InModes success contrasts with other Israeli medical aesthetic devices companies that failed to reach unicorn status and were eventually sold for lower valuations.
Public Trading
growth-positive
Medical device co InMode raises $70m in Nasdaq IPO
Israeli aesthetic medical device company InMode has raised $70 million in its Nasdaq IPO. The company sold shares at $14, reflecting a valuation of $450 million. InMode develops light, laser, and radiofrequency-based devices for minimally invasive aesthetic and medical treatments. The company had revenue of $100 million in 2018, almost double the figure for 2017. In the first quarter of 2019, it posted revenue of $30 million, representing growth of 46%. The company attributes this to greater direct marketing activity in North America.
InvestmentPublic Trading
growth-negative
InMode Opens Below IPO Price
InMode Ltd. made its public debut on NASDAQ through an IPO. The companys shares opened at $13.50 after being priced at $14 per share. InMode is a provider of energy-based, minimally-invasive surgical aesthetic and medical treatment solutions. Barclays and UBS Investment Bank are the joint book-running managers for the offering.
Public Trading
growth-positive
Medical device co Inmode seeks $75m in Nasdaq IPO
Inmode, a developer of aesthetic and medical treatment devices, is planning to raise $75 million on Nasdaq with a valuation of $400-500 million. The company had revenue of $100 million in 2018 and posted a net profit of $22.4 million. In the first quarter of 2019, it achieved revenue of $30 million, representing a growth of 46%. Inmode expects to report revenue of up to $38.8 million for the second quarter of 2019. The company has $82.8 million in cash at the end of the second quarter. Moshe Mizrahy is the chairman and CEO of Inmode.
InvestmentPublic Trading
Medical Aesthetic Devices Manufacturer InMode Gearing Up for Nasdaq IPO
Growth-Positive
InMode Announces PRS Publication and Launch of Aviva Technology For The Women's Health and Wellness Market
InMode Ltd., a global provider of energy-based solutions, has announced new developments for the womens health and wellness market. The company has published the results of a study on post-partum pelvic floor restoration using its Votiva bipolar RF device. The study showed significant improvement in maximal pelvic floor contraction and confirmed the safety of radiofrequency for the treatment of pelvic floor dysfunction. InMode has also launched Aviva, a minimally invasive procedure that restores the function and appearance of the vulva, offering a non-excisional alternative to a labiaplasty.
CustomersExpand
growth-positive
InMode Announces Publication in Aesthetic Surgery Journal: The First Results of A New Combined Treatment for Skin Laxity
InMode Ltd. announces the publication of the results of its new combined protocol for the treatment of skin laxity. The article highlights the effectiveness of InModes Morpheus8 and FaceTite devices in providing significant skin contraction and subdermal adipose remodeling. The combination of these two treatments, known as EmbraceRF, offers a solution for patients who do not want major surgery or are not yet candidates for a full face or neck lift. The publication was written by leading plastic surgeons and demonstrates the effectiveness of InModes minimally invasive and RF fractional technologies. InMode is a global provider of innovative medical technologies, specializing in RF-based devices for various medical fields.
Customers
growth-positive
Dr. Erez Dayan is One of the First Plastic Surgeons Internationally to Offer Newest Advancement AccuTite by InMode
Dr. Erez Dayan at Avance Plastic Surgery Institute introduces AccuTite, the smallest minimally-invasive radio-frequency assisted lipolysis tissue remodeling device. AccuTite aims to revolutionize in-office procedures by offering a solution for tissue remodeling without excisional surgery. It can be done under local anesthesia with little or no visible scarring. Dr. Dayan is among the first Plastic & Reconstructive Surgeons to use the AccuTite device.
Customers
growth-positive
Dr. Bruce Katz First Dermatologist in New York City to Offer Newest Advancement: AccuTite by InMode
Dr. Bruce Katz, medical director of JUVA Skin and Laser Center, introduces AccuTite, a minimally-invasive tissue remodeling device, to his practice. AccuTite allows treatment of delicate areas with pinpoint accuracy and minimal downtime. The effects can be seen immediately, with continuing improvements over time. The addition of AccuTite expands the practices options for natural-looking solutions. Dr. Katz is excited to offer this small skin tightening device to patients.
Partners
growth-positive
InMode Launches AccuTite, Newest Minimally Invasive Technology
InMode Ltd. introduces AccuTite, a new RFAL device for minimally invasive procedures. The device offers precise heating and pinpoint accuracy for face and body areas, with little scarring and minimal downtime. The effects of treatment can be seen immediately and can last up to 12 months. InMode aims to meet the growing demand for minimally invasive aesthetic and wellness solutions. The company continues to develop innovative solutions and provide the latest medical advancements in the field of RF technologies. The article does not mention any specific partners, customers, valuation amount, acquisition amount, investment amount, or layoffs. The event described in the article took place on April 15, 2019.
CustomersExpand
https://www.marketwatch.com/press-release/candela-and-inmode-announce-settlement-of-patent-infringement-lawsuit-2019-03-20
growth-positive
InMode Receives Notice from the FDA of Satisfactory Address of the FDA Letter
InMode Ltd. announced that the FDA has accepted their response to the It Has Come to Our Attention letter, indicating satisfactory address of all items. The company will continue to market their Votiva platforms in compliance with FDA guidelines and regulations. InMode is a global provider of energy-based aesthetic solutions, specializing in radiofrequency energy technology for adipose tissue remodelling. They offer a range of procedures including liposuction, skin tightening, face and body contouring, ablative skin treatments, and womens health and wellness procedures. The company is committed to developing products for the growing womens health and wellness market.
Partners
growth-positive
InMode BodyTite Defines the Treatment Gap Solution In Aesthetic Surgery Journal
InMode Aesthetic Solutions, a leader in aesthetic medicine and technology, was featured in the Aesthetic Surgery Journal for the popularity and success of Radio-Frequency Assisted Liposuction. The article discusses the clinical application of radio frequency energy via the BodyTite device on soft tissues during suction lipectomy, its effect on soft tissue contraction, and its use in aesthetic contouring. The publication highlights InModes leadership in the minimally invasive category and their ability to provide a solution for patients who do not qualify for traditional liposuction. InModes technological advancements have become the new standard in the radio-frequency aesthetic market.
Customers
growth-positive
InMode Aesthetic Solutions Launches A New Concept for Subdermal Adipose-Remodeling of the Face, EmbraceRF and Morpheus8
InMode Aesthetic Solutions introduces EmbraceRF, a new facial contouring technique that targets the neck and face. The technique combines InModes proprietary technologies, FaceTite and Morpheus8, to address a treatment gap in current modalities. EmbraceRF allows plastic surgeons to treat patients who do not have bad enough skin for a facelift and not good enough skin elasticity for liposuction. The procedure involves subdermal adipose-remodeling of the face, which is achieved through the strategic molding of fat using heat generated by FaceTite and the Morpheus8 device. EmbraceRF provides impressive results in a 45-minute procedure with minimal downtime and permanent results. InMode has expanded its reach and developed a network of physicians who have adopted the technology into their practices.
CustomersPartners
InMode Team
Employee Info
| Employees (range) | 500+ |
| Exact count | 517 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 13 classification IDs that could be used for matching.
InMode Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 92/100 |
| Missing | markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 514073618 |
| Crunchbase | inmode |
| Phone | +97249097473 |
| Creator | Tamar Weiss |
| Creator email | tamar.e.weiss@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-05-27T00:00:00.000Z |
| Created | 2014-07-21T00:00:00.000Z |
| Status detail | Public on NASDAQ on Aug, 2019; |